

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1711992> since 2021-04-19T12:37:21Z

*Published version:*

DOI:10.1016/j.jtho.2019.03.029

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Journal of Thoracic Oncology

## Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma --Manuscript Draft--

<b>Manuscript Number:</b>	JTO-D-18-01716R1
<b>Full Title:</b>	Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma
<b>Article Type:</b>	Original Article
<b>Keywords:</b>	malignant pleural mesothelioma; Tumor-infiltrating lymphocytes; T-regulatory cells; myeloid-derived suppressor cells; immune checkpoints
<b>Corresponding Author:</b>	Chiara Riganti, MD Universita degli Studi di Torino Dipartimento di Chimica Torino, ITALY
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Universita degli Studi di Torino Dipartimento di Chimica
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Iris C Salaroglio, PhD
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Iris C Salaroglio, PhD Joanna Kopecka, PhD Francesca Napoli, PhD Moinca Pradotto, PhD Francesca Maletta, MD Lorena Costardi, MD Matteo Gagliasso, MD Vladan Milosevic, PhD Preeta Ananthanarayanan, MSc Paolo Bironzo, MD, PhD Fabrizio Tabbò, MD Carlotta Francesca Cartia, MD Erika Passone, MD Valentina Comunanza, PhD Francesco Ardisson, MD Enrico Ruffini, MD Federico Bussolino, MD, PhD Luisella Righi, MD, PhD Silvia Novello, MD, PhD Massimo Di Maio, MD Mauro Papotti, MD Giorgio Vittorio Scagliotti, MD

	Chiara Riganti, MD
<b>Order of Authors Secondary Information:</b>	
<b>Manuscript Region of Origin:</b>	ITALY
<b>Abstract:</b>	<p><b>Introduction.</b> A comprehensive analysis of the immune-cell infiltrate collected from pleural fluid and from biopsies of malignant pleural mesothelioma (MPM) may contribute to understand the immune-evasion mechanisms related to tumor progression, aiding in differential diagnosis and potential prognostic stratification. Till now such approach has not routinely been verified.</p> <p><b>Methods.</b> We enrolled in 275 patients with an initial clinical diagnosis of pleural effusion. Specimens of pleural fluids and pleural biopsies used for the pathological diagnosis and the immune-phenotype analyses were blindly investigated by multi-parametric flow cytometry. The results were analyzed by Kruskal-Wallis test. The Kaplan-Meier and log-rank tests were used to correlate immune-phenotype data with patients' outcome.</p> <p><b>Results.</b> The cut-offs of intra-tumor T-regulatory (Treg; &gt;1.1%) cells, M2-macrophages (&gt;36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; &gt;5.1% and 4.2%, respectively), CD4+PD1+ (&gt;5.2%) and CD8+PD1+ (6.4%) cells, CD4+LAG-3+ (&gt;2.8% ) and CD8+LAG-3+ (&gt;2.8%) cells, CD4+TIM-3+ (&gt;2.5%) and CD8+TIM-3+ (&gt;2.6%) cells discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. The presence of intra-tumor MDSC contributed to the anergy of tumor-infiltrating lymphocytes (TILs). The immune-phenotype of pleural fluid cells had no prognostic significance. By contrast, the intra-tumor Treg and MDSC levels significantly correlated with progression-free and overall survival, the PD-1+/LAG-3+/TIM-3+ CD4+TILs correlated with overall survival.</p> <p><b>Conclusions.</b> A clear immune-signature of pleural fluids and tissues of MPM patients may contribute to better predict patients' outcome.</p>

Torino, 10/03/2019

To the attention of  
Prof. Thomas John  
Associate Editor  
Journal of Thoracic Oncology

Dear Professor John,

We resubmit our manuscript related to the experimental work entitled “**Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma**” (JTO-D-18-01716).

In accordance with the Reviewers’ comments, we have extensively revised the manuscript and figures. A version with changes highlighted in red and a clean version are included.

We would like to take this opportunity to thank the Reviewers for their valuable comments. The review process has contributed to greatly improve the overall quality of the manuscript.

We hope that the revised version will be suitable for publication in Journal of Thoracic Oncology.

The presented data were obtained as part of an original research. The manuscript has not been published previously and is not being considered concurrently by another journal.

The conflict of interest of each Author has been carefully amended.

Chiara Riganti

**Corresponding author:** Dr. Chiara Riganti, Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy; phone: +39116705857; fax: +39116705845; email: [chiara.riganti@unito.it](mailto:chiara.riganti@unito.it)

## Reply to Reviewer 1

*Reviewer #1: I reviewed the manuscript by Salaroglio et al on the "Potential diagnostic and predictive role of micro-environment in malignant pleural mesothelioma". In their work they look at the immunologic micro environment between the pleural effusions or tissue of patients with mesothelioma, other cancers or benign effusions. Their work is strengthened by the functional assays; however, there are limitations that preclude its publication at this time as described below.*

*1) Why were both parametric and non-parametric statistics used in a small retrospective cohort. Typically, non-parametric statistics are more meaningful in this situation.*

Although we checked the normality distribution of each parameter with the D'Agostino and Pearson test, and all parameters had a Gaussian distribution or approximation in pleuritis and pleural malignant mesothelioma (MPM) groups, following the Reviewer's comment, we applied a non-parametric (Kruskal Wallis) test to the comparisons. We re-calculated the statistical significance applying this non-parametric assay (GraphPad PRISM 5.0 software). We modified abstract (page 3, line 4), Materials and Methods (page 11, line 2), Figures and legends, accordingly.

To correlate these values with progression-free survival (PFS) and overall survival (OS), we divided the population according to the median value, applying the log-rank test, because there are not previously established cut-offs dividing patients with high or low immune-parameters reported in the literature and the size of the cohort analyzed was small.

*2) How and why were a sample size calculated? This is typically done for prospective trial design, not correlative analyses from a retrospective cohort. However, the results of the sample size calculations utilized?*

We apologize for not having clearly explained how the sample size was calculated. We modified the Materials and Methods section accordingly (page 10, line 20).

We agree with the Reviewer's comment that sample size is typically calculated for prospective trial design. In our case, sample size was calculated "prospectively" (i.e. before performing the laboratory determinations). In detail, before starting the patient enrollment, we calculated the sample size necessary to achieve significant results in MPM group, setting significance level ( $\alpha$  error probability)  $\leq 0.05$ , power ( $1-\beta$  error probability) = 0.80, effect size  $\rho = 0.40$ , using the G\*Power Software ([www.gpower.hhu.de](http://www.gpower.hhu.de)). The sample size required was  $34 \pm 2$  for MPM group. We thus analyzed 49 samples from MPM pleural fluid, 33 samples from MPM pleural tissue. The discrepancy between the required minimal number of samples (34) and the analyzed samples (49) in the pleural fluid group was due to the fact that the pathologists performing the diagnosis and the researchers analyzing the immune-infiltrate worked in a blind-manner. The immune-infiltrate analysis was always performed before the pathological diagnosis was known. Given the low frequency of MPM, we had to enrolled 275 patients who received diagnostic thoracoscopies with an initial clinical diagnosis of pleural effusion (page 6, line 24), to achieve the required sample size of patients with a confirmed pathological diagnosis of MPM.

*3) Were other grouping strategies explored other than the median cutoff method described?*

In order to test the association of the immune-parameters analyzed with patients' outcome (PFS and OS), we did not explore grouping strategies other than the division in 2 categories using the median as cutoff. In fact, in literature there are no previously reported and validated cut-off the for the immune-phenotype parameters analyzed. Grouping the patients according to tertiles or quartiles could be significantly limited by the small sample size (n=49 MPM derived from pleural fluid; n =33 MPM

derived from pleural tissue). Indeed dividing by tertiles and quartiles such small cohort, implies a very low number of patients (e.g. 3-5) attributed to each subgroup.

The definition of the optimal cut-off was beyond the scopes of this analysis. A larger prospective study is ongoing at our Institution, with the aim of validating the clinical significance of the immune-phenotypic signature found in this work. Different grouping strategies will be applied to define in a more robust way the correlations between immune-phenotypic parameters, patients clinical history, mutational profiling, response to therapy and clinical outcome.

We modified Material and Methods (page 11, line 8) and Discussion (page 15, line 6; page 17, line 16).

4) For Figures 1-3, Supplemental Figure 3, the labeling is not reader friendly. The values of the asterisks, circles or hash symbols change based on the figure, and I cannot always tell what is being compared by looking at the figure.

We reported the statistical significance in uniform way. Asterisks are referred to the comparison of MPM or pleural metastases of malignant tumors (MTS) towards pleuritis; circles are referred to the comparison of MPM towards MTS (Figure 1-5, new Supplementary Figure 4). In Figure 3, panels D-F, hash symbols are referred to the comparison of Gr-MDSC and Mo-MDSC from MPM patients cultured with T-cytotoxic lymphocytes from pleuritis patients towards Gr-MDSC and Mo-MDSC from pleuritis patients cultured with T-cytotoxic lymphocytes from the same MPM patient.

We modified the legends of main figures and supplementary figures accordingly.

5) Also, in regards to the figures, since the authors are claiming cut-offs for groups, it would be useful to display these results in a format other than bar and line graphs as recommended by statisticians:

<https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002128>

Without this type of display, I cannot tell if parametric tests are appropriate since the authors do not state that they checked the normality of their data.

We modified all the bar and line graphs as the Reviewer suggested, using GraphPad PRISM 5.0 software. To allow a better visualization of the cut-off mentioned in the text, we added them in Figure 1 (panels D, F), Figure 2 (panels B, D, F, H), new Supplementary Figure 5 (panels A-F).

We checked the normality of our data by applying the D'Agostino and Pearson test. The results are reported in the Table below.

	Normality distribution results					
Figure 1	pleuritis fluid	pleuritis tissue	MPM fluid	MPM tissue	MTS fluid	MTS tissue
A	Yes	Yes	Yes	Yes	Yes	too small
B	Yes	Yes	Yes	Yes	Yes	too small
C	No	Yes	Yes	Yes	Yes	too small
E	Yes	Yes	Yes	Yes	Yes	too small
Figure 2						
A	No	No	Yes	Yes	Yes	too small
C	No	Yes	Yes	Yes	Yes	too small
E	No	Yes	Yes	Yes	Yes	too small
G	No	Yes	Yes	No	No	too small
Figure 3						
A	Yes	Yes	Yes	Yes	too small	too small
B	Yes	Yes	Yes	Yes	too small	too small
C	No	Yes	Yes	Yes	too small	too small

D	Yes	Yes	Yes	Yes	too small	too small
E	Yes	Yes	Yes	Yes	too small	too small
F	Yes	No	Yes	Yes	too small	too small
Figure 4						
A	Yes	No	Yes	No	Yes	No
B	Yes	Yes	Yes	No	too small	too small
C	Yes	No	Yes	Yes	Yes	Yes
D	Yes	No	Yes	No	too small	too small
E	Yes	No	Yes	No	Yes	No
F	Yes	No	Yes	Yes	too small	too small
G	Yes	Yes	Yes	Yes	Yes	No
H	Yes	Yes	Yes	Yes	Yes	No
Figure 5						
A		Yes		Yes		Yes
B		Yes		Yes		Yes
C		No		Yes		Yes
D		No		Yes		No
Figure S1A	No	No	Yes	No	Yes	too small
Figure S1A	No	Yes	No	No	No	too small
Figure S2	Yes	Yes	Yes	Yes	No	too small
Figure S3	Yes	Yes	Yes	Yes	No	too small

We added a statement on the normality test used in the Materials and Methods (page 11, line 1). However, as previously specified, following Reviewer's comment, we conservatively decided to perform non-parametric tests.

6) *The conclusion that MDSCs are the primum movens of MPM is far too strong since there are no models to demonstrate that they are necessary and sufficient to drive immunosuppression in this malignancy. Previously published data on PD-L1 expression suggest that this immune checkpoint is also a significant driver with prognostic significance.*

We agree with the Reviewer's criticism, since our experiments prove that MDSC play an important role but are not the only necessary and sufficient finding to determine immune-suppression in MPM. We smoothed the sentence commenting our data on MDSC role (Discussion, page 16, line 5). We already mentioned the role of PD-L1 as a mediator of immune-suppression and as a marker of poor prognosis in MPM (Introduction, page 5, line 20; references 11, 12, 31 and 32 in the previous version, references 20, 21, 22, 23 in the revised version).

7) *Also, I think it is too strong of the conclusion that the cut offs presented can be used to differentiate the groups of patients included in the study. Without discovery and validation cohorts, these conclusions cannot be made. The concluding paragraph about using these values to differentiate challenging clinical cases cannot stand as written.*

We recognize that we cannot propose the cut-off identified in our study as means to differentiate the patients' groups. As specified above, a larger prospective study, including a discovery and validation cohort, is ongoing to evaluate the potential use of the immune-phenotypic signature identified to differentiate the challenging clinical cases.

We rewrote the final paragraph accordingly (page 16, line 17).

8) *The authors do not account for multiplicity. So many statistical test were performed yet know adjustments were made for the large number of comparisons performed. There are either needs to be an explanation for why no adjustments were made or a more stringent P value needs to be applied.*

Given the exploratory nature of the study, we did not make adjustments.

Following the Reviewer suggestion, we applied a more stringent p value ( $p < 0.01$  instead of  $p < 0.05$ ), to account, at least partially, for the multiplicity of tests. Only the analysis of survival, considering its exploratory nature, was performed with a  $p < 0.05$  cutoff.

We re-calculated the statistical significance with this cut-off and modified Figures and Materials and Methods (page 11, lines 5 and 14) accordingly.

9) *Finally, the use of "predictive" in the title is not appropriate. Predictive markers suggest which patients would benefit from therapy. Whereas prognostic markers are suggestive of survival outcomes.* We modified the title changing "predictive" role into "prognostic role".

*Minor*

1. *The use of some abbreviations is not common, such as PD-1L*

We checked the abbreviations. In particular we corrected the abbreviation PD-1L into PD-L1.

2. *Copy editing would help with spelling and grammar (page 5, line 44, "maaged")*

We checked spelling and grammar throughout the manuscript.

## **Reply to Reviewer 2**

*Reviewer #2: In this, the age of immunotherapy a comprehensive knowledge of the immune-evasion mechanisms has the potential to discover parameters related to tumour progression and prognostication. FACS assessment of TILs provides a detailed description of T cell subsets, their differentiation and immune checkpoint expression. In this paper by Prof. Riganti et al, the authors have conducted a broad explorative analysis on the immune microenvironment of pleural fluid and pleural biopsy specimens of patients with suspected mesothelioma. They uncovered some features in the immune profile that may potentially be of use in differentiating mesothelioma from pleuritis and secondary deposits in the pleura They found a prognostic role for intra-tumor Treg and MDSC levels and PD-1+/LAG-3+/TIM-3+ CD4+TILs. Immune-phenotype of pleural fluid cells showed no prognostic significance.*

*The authors are to be congratulated for their exhaustive effort and a well written manuscript.*

*I think this paper helps further define the immune evasive environment in mesothelioma and sheds some light on the prime roles of MDSC and tumour associated macrophages. More importantly, it helps delineate the differences in the immune microenvironment in mesothelioma versus pleuritis. This could be helpful in the diagnosis of difficult cases. I do however think that the latter findings need to validated in larger independent cohorts.*

*Some points to clear out:*

1) *A flow chart (perhaps in the supplemental data section) showing the number of samples collected, the numbers included and reason/s for exclusion would be very helpful as this information is not clear.*

*Was the collection of samples prospective? Was there a reason why only a proportion had both pleural fluid and tissue available for analysis?*

Following the Reviewer's suggestion, we added a flow chart (new Supplementary Figure 1) and we added the missing information about collecting and processing samples (page 6, line 24), and inclusion criteria (page 8, line 22), in the revised manuscript.

We enrolled 275 patients with an initial clinical diagnosis of pleural effusion of unknown origin. The patients enrollment was terminated when we reach a sample size with an adequate power in the MPM patient cohort (see reply to Reviewer 1, point 2).

Two aliquots of pleural fluid and pleural tissue were collected by thoracic surgeons at the same time for each patient. One aliquot was used for diagnostic purposes according to local pathology guidelines, the second one was used for the research study. Priority was given to the diagnostic workup, the left-over was dedicated to the research study. On the basis of the pathologists' decision, in case of limited volume of pleural fluid or limited dimension of pleural tissue, both aliquots were dedicated to the diagnostic workup. In accordance with the above reported criteria, 183 pleural fluids and 119 pleural biopsies were available for the research study.

The research unit performed a technical feasibility check of the immune-analysis for each sample and established to include in the study only samples with  $\geq 1 \times 10^6$  viable (i.e. Trypan-blue negative) cells in the supernatants or adherent in flask. Preliminary set-up experiments indicated that  $\geq 1 \times 10^6$  viable cells were the minimal number required allowing to acquire  $1 \times 10^5$  cells/staining, to measure each population or immune-parameter on each sample. Samples with  $\leq 1 \times 10^6$  viable cells were excluded, since they did not allow to acquire  $1 \times 10^5$  cells/staining. Acquiring  $< 1 \times 10^5$  cells/staining reduced the accuracy of detection of rare immune-populations (i.e.  $< 10\%$  cells present in the immune-infiltrate) or rare immune-checkpoints ( $< 10\%$  positive cells).

According to this inclusion criterion, from all the collected samples 63 non-malignant pleuritis, 49 MPM and 32 MTS for pleural fluid; 16 non-malignant pleuritis, 33 MPM and 5 MTS for pleural tissue biopsies were included in the present study. 9 patients with diagnosed pleuritis and 20 patients with diagnosed MPM group had both pleural fluid and pleural tissue available.

*2) Were the arbitrary cut-offs just the medians for each of the parameters?*

The cut-offs indicated in the abstract, in the text and in Figure 1 (panels D, F), Figure 2 (panels B, D, F, H), Supplementary Figure 5 (panels A-F), were fixed in order to discriminate patients with MPM from patients with pleuritis with the highest sensitivity. Using the established cut-offs, we yielded a sensitivity of 100% (i.e. 0% false negative for all the parameters), and a specificity between 89% and 100% (i.e. 11% false positive for Treg and Mo-MDSC; 0% false positive for all the remaining parameters).

We better specified this point in the Abstract (page 4, line 6) and Materials and Methods (page 11, line 6). We reported *in extenso* throughout the Abstract and the Results section all the cut-offs which met the sensitivity and specificity criteria indicated above. We reported the cut-off in the figures and figures legends, along with the values of false negative, false positive, sensitivity and specificity.

In Table 1, Supplementary Figures 6, 7 and 8, we used the medians as cut-offs, to group patients with "high" or "low" immune-parameters and correlate the meaning of the immune-parameters evaluated with PFS and OS, because of the absence of established cut-offs in the literature and the limited sample size of the cohort.

*3) We know that there is much inter and intra patient variation in the intensity and composition of TILs, do the authors believe that this may have an effect on the ability to differentiate different mesothelioma samples from pleuritis and secondaries?*

The intra-tumor immune-infiltrate analysis has been performed on a small cohort of MPM (27 epithelioid MPM, 3 sarcomatous MPM, 3 biphasic MPM). We did not see correlations between different intensity/compositions of TILs, different anamnestic features (age, sex, smoking status, presence or absence of asbestos exposure, professional or environmental asbestos exposure, Supplementary Table 2), different features of MPM samples (e.g. histological type, Supplementary Table 2; mutational profile of each patient, not reported in the manuscript).

We did not divide further the sample into subgroups according to the qualitative and quantitative differences in TILs, to investigate if such differences may have an impact on the differential diagnosis between each MPM subgroup, pleuritis or MTS. Working with such small number of patients could result in statistical biases due to the limited number of patients in each subgroup.

A larger prospective study is currently ongoing at our Institution. The aims of this prospective study are:

- i) to validate the clinical meaning of the immune-phenotypic signature found in this work, defining in a more robust way the correlations between immune-phenotypic parameters, anamnestic information of the patients, MPM histotypes, mutational profiling, response to therapy and clinical outcome;
- ii) to evaluate if the analysis of the immune-parameters identified in this work may be routinely applied in the diagnostic workup to refine the differential diagnosis with pleuritis and MTS.

We commented this point in the revised manuscript (Discussion, page 17, line 19; page 18, line 6).

*4) The prognostic significance of intra-tumor Treg and MDSC levels and PD-1+/LAG-3+/TIM-3+ CD4+TILs is interesting. However, it appears that a multivariate analysis was not done? Are we reasonably confident that these are independent of factors like tumour histological subtype as we know that the immune-microenvironment varies with histology.*

As stated in reply to point 3, we analyzed intra-tumor Treg, MDSC, PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> CD4<sup>+</sup>TILs in a small cohort of MPM. We did not plan a multi-parametric analysis, to avoid possible statistical biases due to the small size of the subgroups analyzed. However, we agree with the Reviewer that multi-parametric analysis will give important information, and we plan to perform such analyses in the ongoing multi-center validation study.

### **Reply to Reviewer 3**

*Reviewer #3: Dr. Salaroglio and colleagues have undertaken a thoughtful analysis of the microenvironment in pleural fluid. They have identified features of pleural fluid that are potentially diagnostic of the etiology of the fluid - pleuritis, mesothelioma, or metastatic malignant disease. I do have several constructive comments as below:*

*1) Please clarify when relative to the clinical course the samples underwent the research testing analyses. The text indicates in parallel. Does that mean that samples were not aggregated for batch testing? Or, rather each and every time there was an effusion this battery of testing was performed?*  
We apologize for not having detailed the clinical course of sample processing. We added the missing information about collecting and processing samples (page 6, line 24), and inclusion criteria (page 8, line 22) in the revised manuscript.

We specified that we performed the whole set of tests for each sample and each time (Materials and Methods, page 9, line 1).

*2) Please include some discussion of the statistical results around the cut-offs described in the results section.*

For the detailed explanation on the choice of the cut-offs, please see the replies to Reviewer 2 (point 2) and Reviewer 1 (point 3).

We commented the choice of such cut-offs in the Discussion (page 14, line 23).

We specified that the aim of the study was to maximize the correct identification of MPM patients, accepting the risk to have sporadic cases of pleuritis identified erroneously as MPM. Since all samples were subjected to the usual pathological diagnosis, the rare cases of pleuritis erroneously diagnosed as MPM - on the basis of immune-phenotyping - could be easily re-verified by the pathologist. The analysis of the immune-parameters was not intended to replace the pathological diagnosis. Our aim was to propose a set of new tests supporting the pathological diagnosis of MPM and a set of new prognostic factors.

*3) There are some contextualization errors throughout the manuscript but within the discussion. For example, the statement that "ctla-4 is an important therapeutic target" and referencing an older single arm study instead of the large randomized placebo-controlled trial of tremelimumab that was negative, casts a mistaken impression around the efficacy of CTLA-4 inhibition in mesothelioma.*

We revised the manuscript to avoid contextualization errors. Specifically, we modified the paragraph on CTLA-4, including the reference on the more recent randomized placebo-controlled trial of tremelimumab (page 5, line 24).

*4) The authors suggest use of these immune profiling measures in border line or difficult to analyze cases but provide no information regarding inclusion of those sorts of cases in the development of this tool. How many of the analyzed specimens were complex or difficult? Were any cases included where the standard analysis was inconclusive? To propose using these standards without demonstrating that they were derived from similar cases is not appropriate.*

We agree that we cannot state that the immune-profiling can be used in border-line or difficult to analyze cases. Indeed, in our study we had no cases where the standard pathological analysis was inconclusive. Only a larger prospective study, currently ongoing at our Institution, may include border-line or difficult to analyze cases and may allow to compare the accuracy of the standard pathological diagnosis and of the immune-phenotype analysis in such cases.

We modified Abstract (page 3, line 15) and Discussion (page 17, line 24) accordingly.

*5) Additionally, the entire cohort is described as having suspected mesothelioma. Please clarify what is meant by this? This certainly limits the generalizability of the results.*

We apologize for the sentence reported in the materials and Methods of the previous version:

“From June 2016 through June 2018 we collected 183 consecutive pleural fluids and 119 pleural biopsies from 275 patients with suspected MPM”

that may have induced a misunderstanding.

Patients who received diagnostic thoracoscopy (n=275) had an initial diagnosis of pleural effusion of unknown origin, as reported in the Abstract (page 3, line 1) and Introduction (page 6, line 18) in the previous version. The samples were processed by the Pathology Unit for the diagnostic workup and by the research unit for the immune-parameters analysis, in a blind manner. The association between pathological diagnosis and immune-phenotype analysis was performed during the final data analysis. Only samples with a certain pathological diagnosis of non-malignant pleuritis, MPM or pleural MTS of other tumors were included in the research study. We clarified this point in the Materials and Methods section (page 7, lines 11 and 24).

*6) Overall the discussion is too long and includes a great deal of immunology background that should be included preferentially in the introduction as it is not specific to the results herein.*

We shortened the Discussion and moved some key immunology background information in the Introduction. The References section was modified accordingly.

**Potential diagnostic and prognostic role of micro-environment in malignant pleural  
mesothelioma**

Iris C. Salaroglio <sup>a,\*</sup>, Joanna Kopecka <sup>a,\*</sup>, Francesca Napoli <sup>b</sup>, Monica Pradotto <sup>c</sup>, Francesca  
Maletta <sup>a,d</sup>, Lorena Costardi <sup>e</sup>, Matteo Gagliasso <sup>f</sup>, Vladan Milosevic <sup>a</sup>, Preeta  
Ananthanarayanan <sup>a</sup>, Paolo Bironzo <sup>a,c</sup>, Fabrizio Tabbò <sup>a,c</sup>, Carlotta F. Cartia <sup>f</sup>, Erika Passone <sup>e</sup>,  
Valentina Comunanza <sup>a,g</sup>, Francesco Ardissonne <sup>f</sup>, Enrico Ruffini <sup>e</sup>, Federico Bussolino <sup>a,g</sup>,  
Luisella Righi <sup>a,b</sup>, Silvia Novello <sup>a,c</sup>, Massimo Di Maio <sup>a,h</sup>, Mauro Papotti <sup>a,d</sup>, Giorgio V.  
Scagliotti <sup>a,c</sup>, Chiara Riganti <sup>a,i</sup>

<sup>a</sup> Department of Oncology, University of Torino, Via Santena 5/bis, 10126, Torino, Italy

<sup>b</sup> Pathology Unit, Department of Oncology at San Luigi Hospital, University of Torino,  
Regione Gonzole 10, 10043, Orbassano, Italy

<sup>c</sup> Thoracic Oncology Unit and Medical Oncology Division, Department of Oncology at San  
Luigi Hospital, Regione Gonzole 10, University of Torino Regione Gonzole 10, 10043,  
Orbassano, Italy

<sup>d</sup> Pathology Unit, Department of Oncology at AOU Città della Salute e della Scienza, Corso  
Bramante 88, 10126, Torino

<sup>e</sup> Thoracic Surgery Unit, Department of Surgery, AOU Città della Salute e Della Scienza,  
University of Torino, Corso Bramante 88, 10126, Torino

<sup>f</sup> Thoracic Surgery Unit, Department of Oncology at San Luigi Hospital, University of Torino,  
Regione Gonzole 10, 10043, Orbassano, Italy

<sup>g</sup> Candiolo Cancer Institute - FPO IRCCS, Candiolo, Department of Oncology, University of  
Torino, SP142, 95, 10060 Candiolo, Italy

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

<sup>h</sup> Medical Oncology Division, Department of Oncology at AOU Ordine Mauriziano di Torino,  
Corso Re Umberto 109, 10128, Torino, Italy

<sup>i</sup> Interdepartmental Center “G. Scansetti” for the Study of Asbestos and Other Toxic  
Particulates, University of Torino, via Pietro Giuria 5, 10126, Italy

\* Equal contribution

**Corresponding author:** Dr. Chiara Riganti, Department of Oncology, University of Torino,  
via Santena 5/bis, 10126, Torino, Italy; phone: +390116705857; fax: +390116705845; email:  
[chiara.riganti@unito.it](mailto:chiara.riganti@unito.it)

#### **Conflicts of interest statement**

Silvia Novello received honoraria for speaker bureau and advisory role from Astrazeneca, BI,  
Roche, Pfizer, MSD, Eli Lilly, Abbvie, Celgene for activities unrelated to the present study.

Giorgio Scagliotti received honoraria for speaker bureau and advisory role from Astrazeneca,  
Roche, Pfizer, MSD, Eli Lilly, Abbvie and travel support from MSD and Bayer for activities  
unrelated to the present study.

The other authors have no conflict of interests

#### **Abstract**

**Introduction.** A comprehensive analysis of the immune-cell infiltrate collected from pleural  
fluid and from biopsies of malignant pleural mesothelioma (MPM) may contribute to  
understand the immune-evasion mechanisms related to tumor progression, aiding in  
differential diagnosis and potential prognostic stratification. Till now such approach has not  
routinely been verified.

1 **Methods.** We enrolled in 275 patients with an initial clinical diagnosis of pleural effusion.  
2  
3 Specimens of pleural fluids and pleural biopsies used for the pathological diagnosis and the  
4  
5 immune-phenotype analyses were blindly investigated by multi-parametric flow cytometry.  
6  
7 The results were analyzed by Kruskal-Wallis test. The Kaplan-Meier and log-rank tests were  
8  
9 used to correlate immune-phenotype data with patients' outcome.  
10

11 **Results.** The cut-offs of intra-tumor T-regulatory (Treg; >1.1%) cells, M2-macrophages  
12 (>36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; >5.1% and  
13  
14 4.2%, respectively), CD4<sup>+</sup>PD1<sup>+</sup> (>5.2%) and CD8<sup>+</sup>PD1<sup>+</sup> (6.4%) cells, CD4<sup>+</sup>LAG-3<sup>+</sup> (>2.8% )  
15  
16 and CD8<sup>+</sup>LAG-3<sup>+</sup> (>2.8%) cells, CD4<sup>+</sup>TIM-3<sup>+</sup> (>2.5%) and CD8<sup>+</sup>TIM-3<sup>+</sup> (>2.6%) cells  
17  
18 discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. The presence of  
19  
20 intra-tumor MDSC contributed to the anergy of tumor-infiltrating lymphocytes (TILs). The  
21  
22 immune-phenotype of pleural fluid cells had no prognostic significance. By contrast, the intra-  
23  
24 tumor Treg and MDSC levels significantly correlated with progression-free and overall  
25  
26 survival, the PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> CD4<sup>+</sup>TILs correlated with overall survival.  
27  
28  
29  
30  
31  
32

33 **Conclusions.** A clear immune-signature of pleural fluids and tissues of MPM patients may  
34  
35 contribute to better predict patients' outcome.  
36  
37  
38  
39  
40

41 **Key words:** malignant pleural mesothelioma; tumor-infiltrating lymphocytes; T-regulatory  
42  
43 cells; myeloid-derived suppressor cells; immune checkpoints  
44  
45  
46  
47

#### 48 **Abbreviations:**

49 DCFDA-AM: 5-(and-6)-chloromethyl-2',7' -dichlorodihydro-fluorescein diacetate-  
50  
51 acetoxymethyl ester; FBS: fetal bovine serum; Gr-MDSC: granulocytic myeloid-derived  
52  
53 suppressor cells; HR: hazard ratio; IDO: 2,3-indoleamine dioxygenase; Mo-MDSC: monocytic  
54  
55 myeloid-derived suppressor cells; MPM: malignant pleural mesothelioma; MTS: metastases;  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

OS: overall survival; PFS: progression free survival; NK: natural killer; NO: nitric oxide; ROS:  
reactive oxygen species; TAM: tumor-associated macrophage; Treg: T-regulatory; TIL: tumor-  
infiltrating lymphocyte.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

1  
2 Malignant pleural mesothelioma (MPM) is an asbestos-related cancer characterized by a long  
3  
4 latency.<sup>1</sup> It has a low mutational burden and the tumor micro-environment rather than the  
5  
6 genetic abnormalities in mesothelial cells may contribute to MPM development and  
7  
8 progression.<sup>2</sup> The MPM micro-environment is rich of immune-suppressive and anergic  
9  
10 immune cells,<sup>4-6</sup> such as T-regulatory (Treg),<sup>7-8</sup> granulocytic and monocytic myeloid-derived  
11  
12 suppressor cells (Gr-MDSC/Mo-MDSC)<sup>5,7</sup> and M2-polarized tumor associated macrophages  
13  
14 (TAMs),<sup>9</sup> that – together with soluble factors, such as cytokines, chemokines<sup>7</sup> and kynurenine,  
15  
16 the product of 2,3-indoleamine dioxygenase (IDO) enzyme<sup>8</sup> – lead to a poor response to  
17  
18 immune-therapy.<sup>10</sup>

19  
20  
21  
22  
23  
24 Several cytokines accumulated in the pleural effusion of MPM patients promote the M2  
25  
26 polarization of macrophages.<sup>11,12</sup> M2/M3-macrophages and<sup>11,13</sup> Gr-MDSC<sup>5</sup> of MPM patients,  
27  
28 as well as MPM cells<sup>14</sup> reduce the proliferation of heterologous CD8<sup>+</sup>T-lymphocytes, by  
29  
30 producing immune-suppressive mediators such as reactive oxygen species (ROS), nitric oxide  
31  
32 (NO) and kynurenine.<sup>5,8,15</sup> MDSC are killed by active CD8<sup>+</sup>T-lymphocytes,<sup>16,17</sup> while either  
33  
34 Treg and MDSC reduce CD8<sup>+</sup>T-lymphocytes activity<sup>5,7,18</sup> and memory CD8<sup>+</sup>T-lymphocytes  
35  
36 recruitment,<sup>19</sup> inducing a vicious immune-suppressive circle.

37  
38  
39  
40  
41 The high expression of immune-checkpoints on T-lymphocytes and of their ligands on MPM  
42  
43 cell has another crucial role in the MPM-induced anergy of tumor-infiltrating lymphocytes  
44  
45 (TILs).<sup>6</sup> The PD-1/PD-L1 axis is the more extensively studied and the most correlated with  
46  
47 early progression and shorter survival.<sup>3,4,20,21,22,23</sup> LAG-3 and TIM-3 have been detected on  
48  
49 CD4<sup>+</sup> and CD8<sup>+</sup>TILs<sup>24</sup> or in formalin-fixed paraffin embedded samples.<sup>25</sup> Despite the high  
50  
51 inter-patient and intra-sample variability,<sup>26</sup> both LAG-3 and TIM-3 contribute to the functional  
52  
53 exhaustion of TILs. Furthermore CTLA-4 has been investigated as a potential therapeutic target  
54  
55 in MPM, but the CTLA-4 inhibitor Tremelimumab did not show higher efficacy than placebo  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

in a double blind phase 2 trial,<sup>27</sup> raising concerns about the role of this immune-checkpoint in the MPM-induced immune-suppression.

The dissection of the immune-environment of MPM is quite difficult and has often twisted conflicting findings for different reasons. For instance, the number of T-cells and macrophages detected in pleural effusion not always mirrors the amount of the same cells infiltrating MPM tissue.<sup>28</sup> Some studies reported the same immune-signature in the MPM pleural effusion and in the peripheral blood,<sup>24</sup> while others did not,<sup>5</sup> raising concerns about peripheral blood as a biological surrogate that reliably reproduces the MPM immune-environment. Indeed, immune cells can be continuously exchanged between pleural cavity and tumor tissue, and/or between peripheral blood and pleural environment. This dynamic immune-environment leads to an inhomogeneous distribution of immune-cells within MPM tissue. Moreover, the immune-environment is exposed to time-changes related to the natural tumor progression and/or to chemotherapy-related effects.<sup>28</sup> Also qualitative and quantitative changes in tumor/stroma ratio may produce a dramatic rewiring in the MPM-infiltrating immune cell subsets.<sup>18</sup> The high intra-patient variability, the intra-tumor heterogeneity,<sup>29</sup> the different timing of analysis may partially justify the divergent results.

A simultaneous analysis of all the immune-populations detectable in the pleural effusion and infiltrating the tissue has never been performed. The present study aims at a comprehensive analysis of the immune-infiltrate detected in the pleural fluid and in the biopsies of pleural tissue, collected during routine diagnostic procedures from patients with pleural effusions of unknown origin, in order to identify an immune-phenotype with diagnostic and prognostic value in MPM patients.

## **Materials and methods**

**Samples collection.** From June 2016 through June 2018 we enrolled 275 patients with an initial clinical diagnosis of pleural effusion of unknown origin. The enrollment of patients was

1 stopped when we have reached the sample size with an adequate power in the MPM patient  
2 cohort (see “Statistical analysis” paragraph). Samples were obtained during diagnostic  
3 thorascopies, at the Thoracic Surgery Division of San Luigi Gonzaga Hospital, Orbassano,  
4 and AOU Città della Salute e della Scienza, Torino, Italy. Two aliquots of pleural fluid and  
5 pleural tissue were collected by thoracic surgeons at the same time for each patient. Each  
6 sample was managed by the Pathology Unit of the two Institutions: one aliquot was used for  
7 diagnostic purposes according to local pathology guidelines, the second one was used for the  
8 research study here reported. In case of limited volume of pleural fluid or limited dimension of  
9 pleural tissue, both aliquots were dedicated to the diagnostic workup. In accordance with this  
10 criterion, 183 pleural fluids and 119 pleural biopsies were available for the research study.  
11 Within all these samples, 63 pathologically diagnosed non-malignant pleuritis, 49 MPM and  
12 32 pleural metastases - MTS - of malignant tumors for pleural fluid; 16 non-malignant pleuritis,  
13 33 MPM and 5 MTS for pleural tissue biopsies met the technical inclusion criteria (see  
14 “Phenotyping of immune cells” paragraph) and were analyzed in this study. 9 patients with  
15 pathologically diagnosed pleuritis and 20 patients with pathologically diagnosed MPM had  
16 both pleural fluid and pleural tissue available for the study. The flow chart of sample collection  
17 and processing is reported in the **Supplemental Figure 1**. The characteristics of samples used  
18 for the immune-phenotyping in the present study are reported in the **Supplemental Table 1**.  
19 The anonymized patients’ history (asbestos exposure and smoking status, whenever available),  
20 the pathological diagnosis and the clinical follow-up (progression free survival, PFS; overall  
21 survival, OS) of MPM patients, performed at the Thoracic Oncology Unit, San Luigi Gonzaga  
22 Hospital, are reported in the **Supplemental Table 2**. All patients with MPM were in advanced  
23 clinical stage and all were treated with standard cytotoxic chemotherapy according to current  
24 guidelines.<sup>30</sup> The researchers performing the immune-phenotyping analyses reported below  
25 worked in a blind manner, being unaware of the pathological diagnosis at the time of the assays.

1 The association between pathological diagnosis, immune-phenotype analysis was performed  
2 during the final data analysis. The Ethics Committee of San Luigi Gonzaga Hospital,  
3 Orbassano, Italy approved the study (#126/2016).  
4  
5

6  
7 **Sample processing and mesothelial/tumor histological analysis.** 50 ml of pleural fluid were  
8 centrifuged at 1200×g for 5 min, washed in PBS containing 1 mg/ml ciprofloxacin (Sigma  
9 Chemicals Co., St. Louis, MO), and re-suspended at  $1 \times 10^6$  cells/ml in Ham's F10 nutrient  
10 mixture medium (Invitrogen Life Technology, Milano, Italy), supplemented with 10% v/v fetal  
11 bovine serum (FBS; Sigma Chemicals Co.), 1% v/v penicillin-streptomycin (Sigma Chemicals  
12 Co.). Tissues were digested in medium containing 1 mg/ml collagenase and 0.2 mg/ml  
13 hyaluronidase (Sigma Chemicals Co.) for 1 h at 37°C. Cells from pleural fluid and digested  
14 tissue were seeded in culture flasks (Becton Dickinson, Franklin Lakes, NJ) for 24 h in  
15 complete medium. After this period, the cells floating in the supernatant, i.e. immune cells in  
16 the pleural fluid or infiltrating the tissue, were collected, counted and analyzed for their  
17 immune-phenotype as detailed below. Adherent cells were analyzed for their  
18 mesothelial/tumor origin: after detaching by gentle scraping, cells were centrifuged at 1200×g  
19 for 5 min, fixed in 4% v/v formalin at 4 °C overnight and stained with the following antibodies:  
20 calretinin (Thermo Fisher Scientific, Waltham, MA), Wilms tumor-1 antigen (Thermo Fisher  
21 Scientific), cytokeratin 5 (Menarini Diagnostics, Bagno a Ripoli, Italy), podoplanin (Dako,  
22 Santa Clara, CA), pancytokeratin (Dako), epithelial membrane antigen (EMA, Dako), carcino-  
23 embryonic antigen (CEA, Dako), using an automated immunostainer (Benchmark Ventana  
24 Medical Systems, Tucson, AZ).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 **Phenotyping of immune cells.** From all the samples available for research purpose, only  
53 samples with  $\geq 1 \times 10^6$  viable (i.e. Trypan-blue negative) cells in the supernatants or adherent  
54 in flask were included in the analysis. Preliminary set-up experiments indicated that  $\geq 1 \times 10^6$   
55 viable cells was the minimal number required allowing to acquire  $1 \times 10^5$  cells/staining, in order  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 to perform the whole set of the immune-phenotyping tests on each sample. Samples with  $\leq$   
2  $1 \times 10^6$  viable cells were excluded, since they did not allow to acquire  $1 \times 10^5$  cells/staining. The  
3  
4 supernatants were centrifuged at  $1200 \times g$  for 5 min, the pellet was washed in PBS and re-  
5  
6 suspended in PBS containing 5% v/v FBS. A three- and four-color flow cytometry was  
7  
8 performed, with the appropriate combinations of antibodies (all diluted 1:10, from Miltenyi  
9  
10 Biotec, Teterow, Germany if not otherwise specified) against: CD3 (mouse clone REA613),  
11  
12 CD4 (mouse clone M-T466), CD8 (mouse clone BW135/80) for T-lymphocytes; CD25 (mouse  
13  
14 clone 4E3), CD127 (mouse clone MB1518C9) for Treg cells; CD56 (mouse clone AF127H3),  
15  
16 CD335/NKp46 (mouse clone 9E2) for natural killer (NK) cells; CD19 (mouse clone REA675)  
17  
18 for B-lymphocytes; CD14 (mouse clone TÜK4) and CD68 (mouse clone Y1/82A) for  
19  
20 monocytes and macrophages; CD68 (mouse clone Y1/82A), CD208 (mouse clone DCN228)  
21  
22 and Arginase-1 (sheep polyclonal, # IC5868A, R&D Biosystems; Minneapolis, MN) for M2-  
23  
24 polarized macrophages; CD68 (mouse clone Y1/82A), CD86 (mouse, clone FM95) and iNOS  
25  
26 (rabbit polyclonal, #SPC-1325, StressMark Biosciences Inc., Victoria, Canada) for M1-  
27  
28 polarized macrophages; CD11b (rat clone M1/70.15.11.5), CD14 (mouse clone TÜK4), CD15  
29  
30 (mouse clone VIMC6) for granulocytic myeloid-derived suppressor cells (Gr-MSDC) and  
31  
32 monocytic myeloid-derived suppressor cells (Mo-MDSC). In each combination staining,  $1 \times 10^5$   
33  
34 cells were analyzed using a Guava® easyCyte flow cytometer (Millipore, Bedford, MA),  
35  
36 equipped with the InCyte software.  
37  
38

39  
40  
41  
42  
43  
44  
45  
46 **Expression of immune-checkpoints and immune-checkpoint ligands.** CD3<sup>+</sup> cells were  
47  
48 isolated from  $1 \times 10^6$  immune cells of the supernatant of each culture with the Pan T Cell  
49  
50 Isolation Kit (Miltenyi Biotec.), washed and re-suspended in PBS containing 5% v/v FBS. The  
51  
52 detection of immune-checkpoints on CD3<sup>+</sup> T-lymphocytes and/or immune-checkpoint ligands  
53  
54 on MPM cells were performed using antibodies for CD279/PD-1 (mouse clone PD1.3.1.3),  
55  
56 CD223/LAG-3 (clone REA351), CD366/TIM-3 (mouse clone F38-2E2), CD152/CTLA-4  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (mouse clone BNI3; all diluted 1:10, Miltenyi Biotec.), CD274/PD-1L (1:100, mouse clone  
2 29E.2A3, BioLegend, San Diego, CA), anti-GAL-9 (mouse, clone 9M1-3, BioLegend). In each  
3 combination staining  $1 \times 10^5$  cells were analyzed using a Guava® EasyCyte flow cytometer  
4 (Millipore), equipped with the InCyte software.  
5  
6

7  
8  
9 **MDSC functional properties.** ROS were measured using the fluorescent probe 5-(and-6)-  
10 chloromethyl-2',7'-dichlorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-  
11 AM), as previously reported.<sup>31</sup> The levels of nitrite, the stable derivative of NO, in cell culture  
12 supernatants were measured by the Griess method.<sup>32</sup> The amount of kynurenine was assessed  
13 by spectrophotometry.<sup>33</sup> The results were expressed as nmoles/mg cellular proteins.  
14  
15

16  
17  
18 **Proliferation and activation of T-lymphocytes co-cultured with MDSC.**  $1 \times 10^4$  sorted intra-  
19 tissue Gr-MDSC and Mo-MDSC were co-cultured for 6 days at a 1:1 ratio with sorted intra-  
20 tissue CD3<sup>+</sup>CD8<sup>+</sup>T-cytotoxic lymphocytes, either autologous or heterologous, as detailed in  
21 the experimental section, in the presence of anti-CD3/anti-CD28 dynabeads (Invitrogen Life  
22 Technologies) to activate lymphocytes. The proliferation of T-lymphocytes was assessed by  
23 adding 1  $\mu$ Ci of [<sup>3</sup>H]thymidine (PerkinElmer, Waltham, MA) 18 h before the end of the co-  
24 cultures, then harvesting the plates and counting the radioactivity by liquid scintillation count.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1 The normality distribution of each parameter analyzed was checked with the D'Agostino and  
2 Pearson test. All parameters had a Gaussian distribution or approximation. However, the results  
3 were conservatively analyzed by the non-parametric Kruskal-Wallis test (GraphPad PRISM  
4 6.0 software). All data in the figures are provided as means±SD. Medians and quartile values  
5 are reported in the figure legends. In order to partially correct for the multiplicity of tests  
6 performed, a conservative  $p < 0.01$  was considered statistically significant. For each parameter  
7 specific cut-off discriminating MPM from pleuritis were calculated in order to have a 100%  
8 sensitivity (0% false negative) and >89% specificity (<11% false positive). To correlate the  
9 immune-parameters with PFS and OS, since there are no previously reported and validated cut-  
10 off values for the immune-phenotypic parameters analyzed, patients were exploratively divided  
11 into "low expressing" and "highly expressing" groups, if their value was below or equal/above  
12 the median value. The Kaplan-Meier method was used to calculate PFS and OS. Log rank test  
13 was used to compare the outcome of each group as hazard ratio (HR, i.e. risk of patient death).  
14 Considering the exploratory nature of the survival analysis, no adjustment for multiplicity was  
15 made, and  $p < 0.05$  was considered statistically significant.

## 36 **Results**

### 39 **High T-regulatory cells/high myeloid-derived suppressor cells discriminate malignant** 40 **pleural mesothelioma from inflammatory pleuritis and secondary pleural tumors**

41 CD3<sup>+</sup>T-lymphocytes represented the prevalent immune population within pleural fluid or  
42 pleural tissue, without differences between samples of pleuritis, MPM or MTS (**Figure 1A**).  
43 CD3<sup>+</sup>CD4<sup>+</sup>T-helper lymphocytes were up to 60% in all the samples, without differences  
44 between patient subgroups (**Figure 1B**). CD3<sup>+</sup>CD8<sup>+</sup>T-cytotoxic lymphocytes, representing  
45 approximately 5% of immune cells in pleural fluids from pleuritis, significantly increased in  
46 MPM and MTS-pleural fluid samples. By contrast they represented up to 50% of TILs in  
47 pleuritis and significantly decreased in MPM and MTS (**Figure 1C**). This trend allowed to

1 discriminate pleuritis (all with CD3<sup>+</sup>CD8<sup>+</sup>cells <6.3% in pleural fluid) from MPM (all with  
2 CD3<sup>+</sup>CD8<sup>+</sup>cells >25% in pleural fluid) (**Figure 1D**). T-reg cells were significantly higher in  
3  
4 both pleural fluid and tissue from MPM patients compared to pleuritis and MTS-derived  
5  
6 samples (**Figure 1E**). A cut-off of >1.4% in pleural fluid and >1.1% in pleural tissue Treg cells  
7  
8 identified 100% (20/20) MPM and excluded 88.8% (8/9) pleuritis (**Figure 1F**). NK and B-  
9  
10 lymphocytes were poorly represented and did not show any differences among groups  
11  
12  
13  
14 (**Supplemental Figure 2A-B**).

15  
16 Also monocytes did not differ (**Supplemental Figure 3**), while pleural fluid and tissue  
17  
18 macrophages were significantly higher in MPM and MTS-derived samples (**Figure 2A**). All  
19  
20 pleuritic samples had <34% macrophages in pleural fluid and <35% in tissue while all MPM  
21  
22 samples were above these thresholds (**Figure 2B**). More relevantly the pro-tumorigenic M2-  
23  
24 macrophages were higher in MPM and MTS compared to pleuritis (**Figure 2C**). According to  
25  
26 these parameters, a clear separation between pleuritis (100% of patients with M2-macrophages  
27  
28 <29% in pleural fluid and <36% in pleural tissue) and MPM (100% of patients with M2-  
29  
30 macrophages >41% in pleural fluid and >44% in pleural tissue) was clearly identified (**Figure**  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
**2D**). Anti-tumorigenic M1-macrophages were lower in both pleural fluid and tissue of MPM  
and MTS compared with pleuritis (**Supplemental Figure 4**).

A significantly higher number of Gr-MDSC (**Figure 2E**) and Mo-MDSC (**Figure 2G**) in  
pleural fluid and tissue was detected in MPM compared to pleuritis and MTS. A clear threshold  
of 5.1% Gr-MDSC in both pleural fluid and tissue discriminated 100% pleuritis from 100%  
MPM (**Figure 2F**). A cut-off of >3.6% Mo-MDSC in pleural fluid and >4.2% in pleural tissue  
identified 100% MPM and excluded 88.8% pleuritis (**Figure 2H**).

### **The intratumor myeloid-derived suppressor cells determine T-lymphocytes anergy**

The MDSC isolated from MPM tissue showed increased production of ROS (**Figure 3A**), NO  
(**Figure 3B**) and kynurenine (**Figure 3C**), compared to those obtained from tissue biopsies of

1 other subgroups. In co-culture with CD8<sup>+</sup>T-cytotoxic lymphocytes from the tissue of the same  
2 patient, both Gr-MDSC and Mo-MDSC derived from MPM reduced CD8<sup>+</sup>T-lymphocytes  
3 proliferation (**Figure 3D**), CD107a positivity (**Figure 3E**) and IFN- $\gamma$  production (**Figure 3F**),  
4 compared to the autologous CD8<sup>+</sup>T-lymphocytes/MDSC-co-cultures derived from the pleuritis  
5 and MTS subgroups. The immune-suppressive properties of either Gr-MDSC and Mo-MDSC  
6 were further demonstrated by co-incubating Gr-MDSC and Mo-MDSC derived from MPM  
7 tissue with heterologous T-lymphocytes derived from patients with pleuritis. In this setting,  
8 proliferation, CD107a positivity and IFN- $\gamma$  production of T-lymphocytes derived from pleuritis  
9 was reduced to the same level of T-lymphocytes derived from MPM (**Figure 3D-F**).

### 21 **A high number of intra-tumor PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> infiltrating lymphocytes is peculiar** 22 **of malignant pleural mesothelioma**

23 The immune-checkpoints PD-1 (**Figure 4A-B**), LAG-3 (**Figure 4C-D**) and TIM-3 (**Figure 4E-**  
24 **F**) were higher on CD4<sup>+</sup>T-helper and CD8<sup>+</sup>T-cytotoxic lymphocytes of MPM compared to the  
25 lymphocytes from pleuritis and MTS, either in pleural fluid and in pleural tissue. The cut-off  
26 values of 6.7% in pleural fluid, 5.2% in pleural tissue for CD4<sup>+</sup>PD1<sup>+</sup> (**Supplemental Figure**  
27 **5A**), 6.3% in pleural fluid, 6.4% in pleural tissue for CD8<sup>+</sup>PD1<sup>+</sup>cells (**Supplemental Figure**  
28 **5B**), 4.9% in pleural fluid, 2.8% in pleural tissue for CD4<sup>+</sup>LAG-3<sup>+</sup> (**Supplemental Figure 5C**),  
29 5.2% in pleural fluid, 2.8% in pleural tissue for CD8<sup>+</sup>LAG-3<sup>+</sup>cells (**Supplemental Figure 5D**),  
30 1.9% in pleural fluid, 2.5% in pleural tissue for CD4<sup>+</sup>TIM-3<sup>+</sup> (**Supplemental Figure 5E**), 2.4%  
31 in pleural fluid, 2.6% in pleural for CD8<sup>+</sup>TIM-3<sup>+</sup>cells tissue (**Supplemental Figure 5F**),  
32 discriminated 100% MPM from pleuritis. In our series, the lymphocytic expression of CTLA-  
33 4 did not differ between each subgroup (**Figure 4G-H**).

34 The higher expression of immune-checkpoints on T-lymphocytes was paralleled by the higher  
35 expression of PD-L1 (**Figure 5A**), LAG-3 (**Figure 5B**), TIM-3 (**Figure 5C**) and GAL-9

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

(**Figure 5D**) on MPM cells compared to pleuritis and – for LAG-3 and TIM-3 – compared to MTS.

### **Specific immune-signatures of intratumor infiltrate have a prognostic value**

Furthermore we investigated the potential prognostic role of the immune-phenotypic parameters that significantly differed between MPM and pleuritis.

The amount of CD3<sup>+</sup>CD8<sup>+</sup> cells, Treg, M2-polarized macrophages, Gr/Mo-MDSC, PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM3<sup>+</sup> CD4<sup>+</sup> or CD8<sup>+</sup> cells present in the pleural fluids did not show any significant correlation with PFS and OS of MPM patients (**Table 1**). As far as the intratumor immune-infiltrate was concerned, the amount of CD3<sup>+</sup>CD8<sup>+</sup> cells and M2 were not associated with any prognostic significance, while high intratumor Treg, Gr-MDSC and Mo-MDSC significantly correlated with shorter PFS and OS (**Table 1; Supplemental Figure 6A-E**). The amount of PD-1<sup>+</sup> and LAG-3<sup>+</sup> CD4<sup>+</sup> cells correlated with a lower OS (**Table 1; Supplemental Figure 7A-C**). The expression of immune-checkpoints on intratumor CD8<sup>+</sup> had no prognostic significance (**Table 1; Supplemental Figure 8A-C**).

### **Discussion**

Specific immune-phenotypic markers on tissue microarrays<sup>20</sup> or fine-needle aspirate<sup>24</sup> are currently investigated to better characterize the immune-environment of MPM. The present study for the first time assessed a comprehensive and multi-parametric analysis of the immune-infiltrate of either pleural fluid and pleural tissue, performed parallelly to the routine diagnostic procedures. Based on flow cytometry assays, our experimental model allows to recover viable cells, coupling the phenotypic analysis with functional assays of adaptive immunity. Moreover, we detected a quite robust immune-signature that discriminates MPM from pleuritis and from pleural metastases secondary to other malignancies. By selecting specific cut-offs for each immune-parameter analyzed with 100% sensitivity and  $\geq 89\%$  good specificity, we maximized the possibility to identify correctly all the MPM patients, accepting the possibility to have

1 sporadic cases of pleuritis erroneously identified as MPM. Since all samples were subjected to  
2 the usual pathological diagnosis, the rare cases of pleuritis erroneously identified as MPM on  
3 the basis of immune-phenotype analysis could be easily re-verified by the pathologist and/or  
4 clinically followed-up more strictly . The analysis of the immune-parameters was not intended  
5 to replace the pathological diagnosis but simply to complement the pathological diagnosis of  
6 MPM with a set of immunological tests and potential new prognostic information. Each  
7 parameter was indeed correlated with PFS or OS, exploratively using the median values as cut-  
8 off since in literature there are no previously reported and validated cut-offs for the parameters  
9 analyzed and the identification of the optimal cutoff was beyond the scope of this analysis.

10 The first relevant finding discriminating MPM from non-malignant pleuritis was the higher  
11 intra-pleural fluid CD8<sup>+</sup>T-lymphocytes coupled with the lower intra-pleural CD8<sup>+</sup>TILs. The  
12 amount of CD8<sup>+</sup>TILs has been associated with adverse<sup>18,34</sup> or good<sup>20</sup> prognosis, but in our case  
13 series, we did not detect any prognostic significance. It is likely that - more than the absolute  
14 number of CD8<sup>+</sup>T-lymphocytes - their functional exhaustion, due to the presence of Treg cells  
15 and MDSC,<sup>7,18</sup> is critical in determining tumor progression and patients' outcome.

16 We identified high Treg cells within pleural fluid and tissue as specific biomarkers of MPM  
17 rather than of benign pleural disease or pleural MTS. The high intra-MPM Treg was a negative  
18 prognostic factor, while the amount of Treg in pleural fluid had no clinical significance, as  
19 reported previously.<sup>18</sup> This data pointed out that the intratumor immune-infiltrate – more than  
20 the immune-population in the pleural effusion – in this case is more reliable in predicting the  
21 patients' outcome.

22 As expected, we did not detect significant differences in overall TAMs between MPM and  
23 metastatic patients. Compared to pleuritis, M2-macrophages were increased in both tumor and  
24 pleural fluid of MPM. The correlations between the number of TAMs or the ratio M2/TAM  
25 and the tumor progression or patients' outcomes<sup>9,18,20,34</sup> are highly discordant. According to

1 our data M2 percentage is not a significant predictor of patients' outcome but it is an immune-  
2 marker highly differentiating MPM from non-malignant conditions, as Gr-MDSC and – to a  
3  
4 lesser extent – Mo-MDSC.  
5  
6

7  
8 In our study, Gr- and Mo-MDSC abrogated proliferation and cytotoxic activity of autologous  
9  
10 TILs and of TILs derived from patients with pleuritis. These data suggest that MDSC mediate  
11  
12 an important role MPM immune-suppression, likely by the increased production of ROS, NO  
13  
14 and kynurenine. Again, only the intratumor-infiltrating MDSC - and not the MDSC of pleural  
15  
16 fluid - are significantly associated with poorer PFS and OS. Taking into consideration the  
17  
18 dynamic exchange occurring between pleural fluid and tumor,<sup>28</sup> pleural fluid can be considered  
19  
20 as a reservoir of immune-suppressive cells: higher is their migration from pleural fluid into the  
21  
22 tumor, higher is the chance to characterize an immune-escape status and predict tumor  
23  
24 progression.  
25  
26  
27  
28

29  
30  
31 Immune-checkpoints expression are other key players of immune-suppression in MPM. The  
32  
33 immunohistochemical expression of PD-L1 and PD-1 is not always reliable as biomarker in  
34  
35 discriminating pleuritis from MPM: PD-L1 expression was absent in benign lesions, but PD-1  
36  
37 resulted more expressed on TILs of non-tumoral samples than in TILs of MPM analyzed by  
38  
39 immunohistochemistry,<sup>23</sup> a finding contrasting with the high percentage of PD-1<sup>+</sup> cells reported  
40  
41 in MPM using flow cytometry.<sup>3,4,6</sup> The type of diagnostic antibody and the abundance of the  
42  
43 immune-infiltrate in the examined sample may explain this discrepancy. The multi-parametric  
44  
45 flow cytometry analysis revealed that the amount of PD-1 expressed in CD4<sup>+</sup> and CD8<sup>+</sup>T-  
46  
47 lymphocytes well discriminates MPM from non-malignant pleuritis, but not from metastatic  
48  
49 cancers, in line with the observation that pleural effusion from lung cancer are also rich of  
50  
51 PD1<sup>+</sup>CD8<sup>+</sup>T-lymphocytes and PD-L1<sup>+</sup>-cancer cells.<sup>35</sup>  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Our data indicate that the expression of PD-1, LAG-3 and TIM-3 in TILs, but not in T-cells in  
2 pleural effusion, correlated with lower OS. The lack of correlation between immune-  
3 checkpoint levels and PFS likely suggests that the accumulation of immune-checkpoint-  
4 positive, anergic lymphocytes occurs at advanced stages in MPM patients and determines  
5 prognosis in the terminal stages only. More interestingly, only PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup>CD4<sup>+</sup>  
6 cells, but not CD8<sup>+</sup> cells, were negative prognostic factors. Since CD4<sup>+</sup> T-cells are a hub in the  
7 engagement of other immune populations, we may hypothesize that a loss of function of CD4<sup>+</sup>  
8 T-lymphocytes impairs the immune-recognition of MPM cells more than a dysfunction in the  
9 effector CD8<sup>+</sup> T-cells, leading to faster progression and reduced survival. Among the immune-  
10 checkpoints analyzed in MPM patients, CTLA-4 was poorly expressed on the surface of T-  
11 lymphocytes. This is likely related to the cytosol localization of CTLA-4 and the high recycling  
12 rate.<sup>36</sup> Our data need to be re-assessed when a staining optimization for intracellular CTLA-4  
13 antigen will be achieved.

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 In conclusion, we propose a comprehensive multi-parametric analysis of several  
33 immunological parameters that define a MPM immune-signature, reliably applied to both  
34 pleural fluid and tissue routinely collected in standard clinical practice. We are aware that our  
35 discriminating cut-off values, although significant, have been obtained in a small patient  
36 cohort, and we emphasize that the identification of the optimal cutoff was beyond the scope of  
37 this analysis. The parameters are now being validated in a larger prospective study, including  
38 discovery and validation cohorts, in order to improve the specificity of the proposed thresholds  
39 and evaluate the possible clinical utility of the immune-parameters found. In such ongoing  
40 study, refined grouping strategies will be adopted, in order to define more accurately the  
41 quantitative values of the immune-phenotypic parameters significantly correlated with patient  
42 survival and other clinical parameters. Only if the validation study will confirm this pilot  
43 experience, the immune biomarkers identified in the present study may be considered as

1 additional parameters to be analyzed - beyond the parameters already adopted to perform MPM  
2 diagnosis - in challenging clinical cases.  
3  
4

5 Of note, this study is the first one aimed to systematically characterize the immune-infiltrate of  
6 pleural fluid and tumor derived from the same patient. Our results indicated that the analysis  
7 of the intratumor immune-infiltrate – better than that of pleural fluid – identifies potential  
8 prognostic factors. Given the high inter-patients and intra-patients variability observed in  
9 MPM, the larger prospective validation study will also clarify if the qualitative and quantitative  
10 differences in the intra-tumor immune-infiltrate may be correlated with specific histological,  
11 cyto-genetic and mutational features. This may contribute to a more accurate patients’  
12 stratification, for a rationale and personalized immune-therapy of MPM.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **Funding**

27 This work was supported by Italian Association for Cancer Research (IG21408 to CR); Italian  
28 Ministry of University and Research (Future in Research program RBFR12SOQ1 to CR; Basic  
29 Research Funding Program, FABR2017 to LR and CR); Italian Ministry of Health (GR-2011-  
30 02348356 to LR; Italian Mesothelioma Network-CCM2012 to GVS), Azienda Ospedaliera “SS.  
31 Antonio e Biagio e Cesare Arrigo” to GVS for the research activity “MESOLINE”, University of  
32 Torino (Intramural Grant 2015 to SN and CR; Intramural Grant 2016 to LR; Intramural Grant  
33 2017 to JK); Fondazione Cassa di Risparmio di Torino (2016-2443 to CR). ICS is a post-  
34 doctoral research fellow supported by the Fondazione Franco e Marilisa Caligara for  
35 Multidisciplinary Sciences, Torino, Italy. VM is a PhD fellow of Erasmus Mundus-ERAWEB  
36 Action 2 program. FN is a student of the Biomedical Sciences and Oncology PhD program.  
37  
38 The funding institutions had no role in the study design, data collection and analysis, or in  
39 writing the manuscript.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

## 60 **Acknowledgments**

1 We are grateful to Mr. Costanzo Costamagna, Dept of Oncology, University of Torino for the  
2 technical assistance.  
3  
4  
5  
6  
7

## 8 **References**

- 9  
10  
11 1. Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the  
12 horizon with novel therapeutic strategies. *Cancer Treat Rev.* 2015;41:27-34.  
13 <https://doi.org/10.1016/j.ctrv.2014.10.007>.  
14  
15  
16  
17  
18 2. Stahel RA, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz  
19 I, Peters S. Searching for targets for the systemic therapy of mesothelioma. *Ann Oncol.*  
20 2015;26:1649-60. <https://doi.org/10.1093/annonc/mdv101>.  
21  
22  
23  
24  
25 3. Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni  
26 P, Schlom J, Guadagni F, Hassan R. Malignant Mesothelioma Effusions Are Infiltrated by  
27 CD3(+) T Cells Highly Expressing PD-L1 and the PD-L1(+) Tumor Cells within These  
28 Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. *J Thorac Oncol.*  
29 2016;11:1993-2005. <https://doi.org/10.1016/j.jtho.2016.07.033>.  
30  
31  
32  
33  
34  
35  
36  
37 4. Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao  
38 X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards  
39 WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpennig KW, Jänne PA, Sholl LM,  
40 Hammerman PS, Wong KK, Bueno R. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural  
41 Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. *Cancer*  
42 *Immunol Res.* 2016;4:1038-48. <https://doi.org/10.1158/2326-6066.CIR-16-0171>.  
43  
44  
45  
46  
47  
48  
49  
50  
51 5. Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B,  
52 Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo  
53 C, Hassan R. Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Mesothelioma Patients. *Clin Cancer Res.* 2018;24:2859-72. <https://doi.org/10.1158/1078->  
2 0432.CCR-17-3757.  
3

4  
5 6. Marcq E, Pauwels P, van Meerbeeck JP, Smits EL. Targeting immune checkpoints: New  
6 opportunity for mesothelioma treatment? *Cancer Treat Rev.* 2015;41:914-24.  
7 <https://doi.org/10.1016/j.ctrv.2015.09.006>.  
8  
9

10  
11  
12 7. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN.  
13 Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune  
14 responses. *Eur Respir J.* 2006;27:1086-95. <https://doi.org/10.1183/09031936.06.00135305>.  
15  
16  
17

18  
19  
20 8. Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, Riganti C. Zoledronic  
21 acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.  
22 *Oncotarget.* 2015;6:1128-42. <https://doi.org/10.18632/oncotarget.2731>  
23  
24  
25

26  
27  
28 9. Cornelissen R, Lievense LA, Maat AP, Hendriks RW, Hoogsteden HC, Bogers AJ, Hegmans  
29 JP, Aerts JG. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid  
30 malignant pleural mesothelioma. *PLoS One.* 2014;9:e106742.  
31 <https://doi.org/10.1371/journal.pone.0106742>.  
32  
33  
34

35  
36  
37 10. Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP. Immunotherapy prospects in the  
38 treatment of lung cancer and mesothelioma. *Transl Lung Cancer Res.* 2014;3:34-45.  
39 <https://doi.org/10.3978/j.issn.2218-6751.2013.11.04>.  
40  
41  
42

43  
44  
45 11. Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG.  
46 Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T  
47 Cell Suppression. *J Thorac Oncol.* 2016;11:1755-64.  
48 <https://doi.org/10.1016/j.jtho.2016.06.021>.  
49  
50  
51

52  
53  
54 12. Chéné AL, d'Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau JF, Cellierin L,  
55 Delneste Y, Grégoire M, Blanquart C. Pleural Effusions from Patients with Mesothelioma  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages. *J Thorac*  
2 *Oncol.* 2016;11:1765-73. <https://doi.org/10.1016/j.jtho.2016.06.022>.

3  
4 13. Jackaman C, Yeoh TL, Acuil ML, Gardner JK, Nelson DJ. Murine mesothelioma induces  
5 locally-proliferating IL-10(+)TNF- $\alpha$ (+)CD206(-)CX3CR1(+) M3 macrophages that can be  
6  
7 selectively depleted by chemotherapy or immunotherapy. *Oncoimmunology.*  
8  
9 2016;5:e1173299. <https://doi.org/10.1080/2162402X.2016.1173299>.

10  
11  
12 14. Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D,  
13  
14 Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello  
15  
16 S, Scagliotti GV, Di Nicolantonio F, Taulli R. Bromodomain inhibition exerts its therapeutic  
17  
18 potential in malignant pleural mesothelioma by promoting immunogenic cell death and  
19  
20 changing the tumor immune-environment. *Oncoimmunology.* 2017;7:e1398874.  
21  
22 <https://doi.org/10.1080/2162402X.2017.1398874>.

23  
24  
25 15. Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function  
26  
27 of myeloid-derived suppressor cells. *Oncoimmunology.* 2015;5:e1004983.  
28  
29 <https://doi.org/10.1080/2162402X.2015.1004983>

30  
31  
32 16. Tan Z, Zhou J, Cheung AK, Yu Z, Cheung KW, Liang J, Wang H, Lee BK, Man K, Liu L,  
33  
34 Yuen KY, Chen Z. Vaccine-elicited CD8<sup>+</sup> T cells cure mesothelioma by overcoming tumor-  
35  
36 induced immunosuppressive environment. *Cancer Res.* 2014;74:6010-21.  
37  
38 <https://doi.org/10.1158/0008-5472.CAN-14-0473>.

39  
40  
41 17. Yu Z, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NTL, Man K, Liu L, Chen Z.  
42  
43 Antigen spreading-induced CD8<sup>+</sup>T cells confer protection against the lethal challenge of wild-  
44  
45 type malignant mesothelioma by eliminating myeloid-derived suppressor cells. *Oncotarget.*  
46  
47 2015;6:32426-38. <https://doi.org/10.18632/oncotarget.5856>.

48  
49  
50 18. Ujiiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug  
51  
52 LM, Adusumilli PS. The tumoral and stromal immune microenvironment in malignant pleural  
53  
54

mesothelioma: A comprehensive analysis reveals prognostic immune markers.

*Oncoimmunology*. 2015;4:e1009285. [https://doi.org/ 10.1080/2162402X.2015.1009285](https://doi.org/10.1080/2162402X.2015.1009285)

19. Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, Trauet J, Copin MC, Dessaint JP, Porte H, Labalette M. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. *BMC Cancer*. 2013;13:e324. <https://doi.org/10.1186/1471-2407-13-324>.

20. Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. *Ann Oncol*. 2018;29:1258-65. <https://doi.org/10.1093/annonc/mdy086>.

21. Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2018;13:124-33. <https://doi.org/10.1016/j.jtho.2017.09.1968>.

22. Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). *PLoS One*. 2015;10:e0121071. <https://doi.org/10.1371/journal.pone.0121071>

23. Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. *Hum Pathol*. 2016;52:9-18. <https://doi.org/10.1016/j.humpath.2016.01.010>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
24. Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, Hammerman PS, Gill RR, Richards WG, Barbie DA, Bass AJ, Bueno R, English JM, Bittinger M, Wong KK. Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. *Sci Rep.* 2016;6:e31745. <https://doi.org/10.1038/srep31745>.
25. Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E, Hens N, Pauwels P, van Meerbeeck JP, Smits EL. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. *Oncoimmunology.* 2016;6:e1261241. <https://doi.org/10.1080/2162402X.2016.1261241>.
26. Marcq E, Waele J, Audenaerde JV, Lion E, Santermans E, Hens N, Pauwels P, van Meerbeeck JP, Smits ELJ. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. *Oncotarget.* 2017;8:89722-35. <https://doi.org/10.18632/oncotarget.21113>
27. Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. *Lancet Oncol.* 2017;18:1261-73. [https://doi.org/10.1016/S1470-2045\(17\)30446-1](https://doi.org/10.1016/S1470-2045(17)30446-1).
28. Lievens LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. *Lung Cancer.* 2017;107:36-40. <https://doi.org/10.1016/j.lungcan.2016.04.015>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
29. Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. *Int J Mol Sci.* 2018;19(4). pii: E1041. <https://doi.org/10.3390/ijms19041041>.
30. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015;26 Suppl 5:v31-9. <https://doi.org/10.1093/annonc/mdv199>
31. Riganti C, Gazzano E, Gulino GR, Volante M, Ghigo D, Kopecka J. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. *Cancer Lett.* 2015;360:219-26. <https://doi.org/10.1016/j.canlet.2015.02.008>.
32. De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. *Mol Cancer.* 2009;8:e108. <https://doi.org/10.1186/1476-4598-8-108>.
33. Campia I, Buondonno I, Castella B, Rolando B, Kopecka J, Gazzano E, Ghigo D, Riganti C. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. *PLoS One.* 2015;10:e0126159. <https://doi.org/10.1371/journal.pone.0126159>.
34. Cornelissen R, Lievense LA, Robertus JL, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. *Lung Cancer.* 2015;88:332-37. <https://doi.org/10.1016/j.lungcan.2015.03.013>.
35. Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients. *Cancer Immunol Immunother.* 2017;66:765-76. <https://doi.org/10.1007/s00262-017-1979-x>.

36. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. *Trends Immunol.* 2008;29:272-79. <https://doi.org/10.1016/j.it.2008.02.011>.

## Figure legends

### Figure 1. Lymphocyte subtypes present in pleural fluid and tissue of malignant pleural mesothelioma

Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same patients were analyzed in parallel. **A-C.** Percentage of total (CD3<sup>+</sup>), T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Data are presented as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 52.00, 61.00, 66.00; pleuritis PT: 15.00, 21.00, 26.75; MPM PF: 52.00, 62.00, 71.00; MPM PT: 37.75, 47.00, 58.75; MTS PF: 51.00, 55.00, 64.00; MTS PT: 36.50, 41.00, 51.50 (panel **A**); pleuritis PF: 39.25, 52.00, 60.50; pleuritis PT: 51.00, 61.00, 67.00; MPM PF: 48.25, 61.00, 70.25; MPM PT: 51.00, 56.00, 71.00; MTS PF: 45.10, 51.50, 60.50; MTS PT: 54.00, 61.00, 67.50 (panel **B**); pleuritis PF: 2.90, 3.75, 5.98; pleuritis PT: 30.00, 41.00, 49.00; MPM PF: 25.00, 29.00, 33.00; MPM PT: 12.00, 15.00, 19.00; MTS PF: 14.50, 20.00, 26.00; MTS PT: 10.50, 11.00, 15.50 (panel **C**). \*\*\*p<0.001: MPM/MTS vs pleuritis; not significant: MPM vs MTS. **D.** Disaggregated data of T-cytotoxic cells percentage in PF and PT from the same patient. Dotted line: 6.3% cut-off value in PF (false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). **E.** Percentage of T-regulatory (Treg; CD4<sup>+</sup> CD25<sup>+</sup>CD127<sup>low</sup>) cells. Data are presented as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 0.90, 1.20, 1.50; pleuritis PT: 0.30, 0.50, 0.90; MPM PF: 2.73, 2.95, 3.48; MPM PT: 2.10, 2.80, 3.25; MTS PF: 1.10, 1.25, 1.50; MTS

PT: 0.75, 1.10, 1.25. \*\*\*p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS.

**F.** Disaggregated data of Treg cells percentage in PF and PT from the same patient. Dotted line: 1.4% cut-off value in PF; dashed line: 1.1% cut-off value in PT (false negative: 0%; false positive: 11%; sensitivity: 100%; specificity: 89%)

**Figure 2. Macrophage and myeloid-derived suppressor cell subtypes present in pleural fluid and pleural tissue of malignant pleural mesothelioma**

Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same patients were analyzed in parallel. **A.** Percentage of macrophages (CD14<sup>+</sup>CD68<sup>+</sup> cells). Data are presented as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 15.00, 19.00, 31.00; pleuritis PT: 21.00, 25.00, 32.00; MPM PF: 49.25, 61.00, 71.00; MPM PT: 41.75, 55.00, 62.25; MTS PF: 48.25, 54.00, 66.25; MTS PT: 48.50, 65.00, 69.50. \*p<0.01, \*\*\*p<0.001: MPM/MTS vs pleuritis. **B.** Disaggregated data of macrophage percentage in PF and PT from the same patient. Dotted line: 34% cut-off value in PF, dashed line: 35% cut-off value in PT (false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). **C.** Percentage of M2-macrophages (CD68<sup>+</sup>CD206<sup>+</sup>Arg1<sup>+</sup> cells). Data are presented as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 17.25, 22.00, 28.00; pleuritis PT: 23.00, 28.00, 34.50; MPM PF: 45.00, 55.00, 62.25; MPM PT: 56.00, 60.00, 68.25; MTS PF: 41.25, 44.00, 57.00; MTS PT: 53.00, 64.00, 65.00. \*\*\*p<0.001: MPM/MTS vs pleuritis. **D.** Disaggregated data of M2-macrophage percentage in PF and PT from the same patient. Dotted line: 29% cut-off value in PF, dashed line: 36% cut-off value in PT (false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). **E.** Percentage of granulocytic myeloid-derived suppressor cells (Gr-MDSC; CD11b<sup>+</sup>CD14<sup>-</sup>CD15<sup>+</sup> cells). Data are presented

1 as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 2.20, 2.80, 3.68;  
2 pleuritis PT: 2.10, 2.60, 3.10; MPM PF: 11.23, 13.05, 17.73; MPM PT: 11.80, 13.15, 17.03;  
3  
4 MTS PF: 3.28, 5.15, 6.30; MTS PT: 4.80, 5.10, 7.70. \*\*\*p<0.001: MPM vs pleuritis;  
5  
6 °°°p<0.001: MPM vs MTS. **F.** Disaggregated data of Gr-MDSC percentage in PF and PT from  
7  
8 the same patient. Dashed line: 5.1% cut-off value in PF and PT (false negative: 0%; false  
9  
10 positive: 0%; sensitivity: 100%; specificity: 100%). **G.** Percentage of monocytic myeloid  
11  
12 derived suppressor cells (Mo-MDSC; CD11b<sup>+</sup>CD14<sup>+</sup>CD15<sup>low</sup> cells). Data are presented as  
13  
14 means±SD. \*\*\*p<0.001: MPM vs pleuritis; °°°p<0.001: MPM vs MTS. Values of 25<sup>th</sup>  
15  
16 percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 2.10, 2.40, 3.45; pleuritis PT: 2.13, 2.75, 3.18;  
17  
18 MPM PF: 5.90, 8.20, 10.20; MPM PT: 8.10, 9.75, 11.28; MTS PF: 1.30, 2.30, 2.90; MTS PT:  
19  
20 1.90, 2.35, 2.80. **H.** Disaggregated data of Mo-MDSC percentage in PF and PT from the same  
21  
22 patient. Dotted line: 3.6% cut-off value in PF, dashed line: 4.2% cut-off value in PT (false  
23  
24 negative: 0%; false positive: 11%; sensitivity: 100%; specificity: 89%).  
25  
26  
27  
28  
29  
30

31 **Figure 3. Intratumor myeloid-derived suppressor cells determines CD8<sup>+</sup> T-lymphocytes**  
32 **anergy**  
33

34  
35  
36 1×10<sup>4</sup> sorted intra-tissue Gr-MDSC and Mo-MDSC derived from pleuritis (n=10), MPM  
37  
38 (n=12) and other tumors metastatizing to pleura (MTS; n=4) were seeded and analyzed after  
39  
40 24 h (panels **A-C**), or co-cultured (panels **D-F**) for 6 days with the sorted intra-tissue  
41  
42 CD3<sup>+</sup>CD8<sup>+</sup>T-cytotoxic lymphocytes of the corresponding patient (autologous setting). When  
43  
44 indicated, Gr-MDSC and Mo-MDSC from MPM patients were cultured with T-cytotoxic  
45  
46 lymphocytes from pleuritis patients (pleu/MPM setting; n=8). **A-C.** Intracellular ROS (**panel**  
47  
48 **A**) were measured fluorimetrically, nitrite (**panel B**) and kynurenine (**panel C**) released in the  
49  
50 supernatants were measured spectrophotometrically. Data are presented as means±SD. Values  
51  
52 of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis Gr-MDSC: 0.59 0.79, 0.94; pleuritis Mo-  
53  
54 MDSC: 0.43, 0.65, 0.80; MPM Gr-MDSC: 2.08, 2.40, 2.78; MPM Mo-MDSC: 1.78, 2.20,  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

2.68; MTS Gr-MDSC: 0.61, 0.72, 0.81; MTS Mo-MDSC: 0.43, 0.66, 0.82 (panel **A**); pleuritis  
 Gr-MDSC: 1.58, 2.00, 2.45; pleuritis Mo-MDSC: 1.60, 2.10, 2.95; MPM Gr-MDSC: 8.20,  
 9.75, 12.25; MPM Mo-MDSC: 6.05, 6.85, 8.55; MTS Gr-MDSC: 1.30, 1.75, 2.65; MTS Mo-  
 MDSC: 1.63, 2.15, 2.45 (panel **B**); pleuritis Gr-MDSC: 0.55, 0.72, 0.82; pleuritis Mo-MDSC:  
 0.72, 0.87, 1.16; MPM Gr-MDSC: 3.73, 4.14, 4.85; MPM Mo-MDSC: 4.25, 5.26, 5.35; MTS  
 Gr-MDSC: 0.59, 0.89, 1.19; MTS Mo-MDSC: 0.78, 1.00, 1.24 (panel **C**). \* $p < 0.01$ , \*\* $p < 0.005$ ,  
 \*\*\* $p < 0.001$ : MPM vs pleuritis; ° $p < 0.01$ , °° $p < 0.005$ , °°° $p < 0.001$ : MPM vs MTS. **D-F**. The  
 proliferation of T-cytotoxic lymphocytes (panel **D**) was measured radiometrically, the  
 percentage of CD8<sup>+</sup>CD107a<sup>+</sup> lymphocytes (panel **E**) was measured by flow cytometry, the  
 amount of IFN- $\gamma$  (panel **F**) in the supernatants was measured by ELISA. The proliferation of  
 T-lymphocytes in the absence of anti-CD3/anti-CD28 dynabeads, used as negative control, was  
 $< 3500$  cpm for all experimental conditions. Data are presented as means $\pm$ SD. Values of 25<sup>th</sup>  
 percentile, median, 75<sup>th</sup> percentile: pleuritis Gr-MDSC: 18.09, 23.12, 26.03; pleuritis Mo-  
 MDSC: 27.53, 30.4, 34.62; MPM Gr-MDSC: 2.42, 4.04, 5.00; MPM Mo-MDSC: 4.03, 5.71,  
 6.84; MTS Gr-MDSC: 16.66, 22.69, 28.46; MTS Mo-MDSC: 23.27, 31.72, 33.96; pleu/MPM  
 Gr-MDSC: 5.33, 5.80, 7.19; pleu/MPM Mo-MDSC: 6.44, 8.25, 11.70 (panel **D**); pleuritis Gr-  
 MDSC: 2.08, 2.60, 2.83; pleuritis Mo-MDSC: 2.48, 3.00, 3.25; MPM Gr-MDSC: 0.40, 0.60,  
 0.80; MPM Mo-MDSC: 0.45, 0.80, 1.05; MTS Gr-MDSC: 1.95, 2.65, 3.05; MTS Mo-MDSC:  
 2.83, 3.05, 3.65; pleu/MPM Gr-MDSC: 0.53, 0.75, 0.80; pleu/MPM Mo-MDSC: 0.40, 0.65,  
 0.88 (panel **E**); pleuritis Gr-MDSC: 409.50, 441, 636.50; pleuritis Mo-MDSC: 459.80, 497.50,  
 521.00; MPM Gr-MDSC: 111.80, 151.00, 203.30; MPM Mo-MDSC: 147.00, 177.00, 236.00;  
 MTS Gr-MDSC: 322.00, 463.50, 506.80; MTS Mo-MDSC: 373.80, 480.00, 585.50;  
 pleu/MPM Gr-MDSC: 168.80, 204.50, 263.80; pleu/MPM Mo-MDSC: 209.80, 298.00, 335.80  
 (panel **F**). \*\* $p < 0.005$ , \*\*\* $p < 0.001$ : MPM vs pleuritis; ° $p < 0.01$ , °° $p < 0.005$ , °°° $p < 0.001$ : MPM

vs MTS in autologous settings; # $p < 0.01$ , ### $p < 0.001$ : pleu/MPM setting vs pleuritis autologous setting.

**Figure 4. Immune-checkpoint expression in T-lymphocytes contained in pleural fluid and pleural tissue**

Cells collected from pleural fluid of patients with pleuritis (n=63), malignant pleural mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from digested pleural tissue of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) were analyzed by flow cytometry. Data are presented as means $\pm$ SD. **A-B.** Percentage of PD-1<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 2.45, 4.60, 5.60; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 2.50, 3.90, 5.50; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 15.53, 18.30, 22.65; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 14.83, 17.65, 21.38; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 7.95, 10.20, 12.30; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 7.03, 9.00, 11.33 (panel **A**); pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 2.10, 3.15, 4.10; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 2.03, 2.90, 4.18; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 10.20, 12.50, 16.15; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 11.28, 15.20, 18.05; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 3.60, 4.30, 6.50; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 3.10, 6.20, 8.15 (panel **B**). \*\*\* $p < 0.001$ : MPM vs pleuritis; ° $p < 0.01$ , °° $p < 0.001$ : MPM vs MTS. **C-D.** Percentage of LAG-3<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1.90, 2.80, 4.15; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 1.90, 2.80, 4.15; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 10.83, 13.35, 16.25; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 8.83, 10.60, 14.05; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 3.88, 7.20, 8.40; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 3.75, 7.15, 8.60 (panel **C**); pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1.50, 1.85, 2.10; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 1.60, 1.80, 2.18; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 8.38, 10.50, 14.28; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 8.10, 10.50, 14.10; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 3.40, 4.60, 5.40; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 2.95, 4.10, 4.65 (panel **D**). \*\*\* $p < 0.001$ : MPM vs pleuritis; ° $p < 0.01$ , °° $p < 0.005$ , °°° $p < 0.001$ : MPM vs MTS. **E-F.** Percentage of TIM-3<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1, 1.80, 2.48; pleuritis

CD3<sup>+</sup>CD8<sup>+</sup>: 0.90, 1.35, 1.70; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 6.10, 7.30, 8.40; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 6.65, 8.30,  
 10.70; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 2.18, 3.85, 4.43; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 1.98, 3.15, 4.13 (panel E); pleuritis  
 CD3<sup>+</sup>CD4<sup>+</sup>: 1.13, 1.50, 2.05; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 1.20, 1.35, 1.58; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 6.18,  
 8.10, 8.53; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 6.78, 9.10, 10.20; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 1.25, 1.60, 2.20; MTS  
 CD3<sup>+</sup>CD8<sup>+</sup>: 1.15, 1.40, 1.85 (panel F). \*\*\*p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001:  
 MPM vs MTS. **G-H.** Percentage of CTLA-4<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic  
 (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis  
 CD3<sup>+</sup>CD4<sup>+</sup>: 1.20, 1.40, 1.90; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 0.90, 1.30, 1.58; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 1.10,  
 1.60, 1.90; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 1.10, 1.20, 1.50; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 1.18, 1.50, 2.10; MTS  
 CD3<sup>+</sup>CD8<sup>+</sup>: 1.20, 1.30, 1.80 (panel G); pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1.10, 1.20, 2.05; pleuritis  
 CD3<sup>+</sup>CD8<sup>+</sup>: 1.25, 1.40, 1.70; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 1.30, 1.80, 2.10; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 1.20, 1.50,  
 1.90; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 1.45, 1.70, 2.38; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 1.13, 1.40, 1.73 (panel H).

**Figure 5. Immune-checkpoint ligands expressed in malignant pleural mesothelioma cells**

Mesothelial cells collected from patients with pleuritis (n=24), malignant pleural mesothelioma  
 cells (MPM; n=33) or cells from different tumors metastatizing to pleura (MTS; n=16), were  
 analyzed by flow cytometry for the expression of PD-L1 (panel A), LAG-3 (panel B), TIM-3  
 (panel C), GAL-9 (panel D). Data are presented as means±SD. Values of 25<sup>th</sup> percentile,  
 median, 75<sup>th</sup> percentile: pleuritis: 2.55, 3.60, 4.35; MPM: 15.05, 17.25, 22.95; MTS: 5.60, 9.30,  
 12.70 (panel A); pleuritis: 1.43, 1.95, 2.83; MPM: 7.40, 9.10, 11.25; MTS: 2.40, 4.10, 5.10  
 (panel B); pleuritis: 1.20, 1.90, 2.73; MPM: 7.35, 8.70, 10.25; MTS: 1.65, 2.40, 5.35 (panel  
 C); pleuritis: 1.30, 2.40, 6.23; MPM: 13.40, 17.20, 21.50; MTS: 4.70, 7.80, 9.25 (panel  
 D).\*\*\*p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS.

**Table 1. Survival analysis according to the immune-phenotypic parameter characterizing mesothelioma patients**

Immune-population	Sample	PFS (months) (95% CI)	p value	OS (months) (95% CI)	p value
CD3 <sup>+</sup> CD8 <sup>+</sup> low vs CD3 <sup>+</sup> CD8 <sup>+</sup> high	PF	6.3±1.6 vs 6.3±1.0 (5.0-8.3)	0.913	10.0±2.2 vs 10.8±1.1 (8.2-12.7)	0.6927
Treg low vs Treg high	PF	6.0±1.1 vs 7.0±1.6 (4.7-8.1)	0.496	10.8±1.6 vs 9.7±1.4 (8.2-12.7)	0.4347
M2 low vs M2 high	PF	7.0±1.3 vs 5.7±1.0 (4.7-7.8)	0.2851	10.9±1.5 vs 9.8±1.9 (8.2-12.7)	0.7424
Gr-MDSC low vs Gr-MDSC high	PF	7.1±1.1 vs 5.6±1.3 (4.6-8.1)	0.3351	10.6±1.4 vs 10.8±2.2 (8.2-13.1)	0.4522
Mo-MDSC low vs Mo-MDSC high	PF	6.8±1.2 vs 5.9±1.4 (4.4-8.1)	0.8755	10.8±1.6 vs 9.4±1.7 (7.9-12.5)	0.5498
CD4 <sup>+</sup> PD-1 <sup>+</sup> low vs CD4 <sup>+</sup> PD-1 <sup>+</sup> high	PF	5.7±1.3 vs 7.3±1.1 (4.7-8.1)	0.713	8.6±1.5 vs 12.4±1.6 (8.2-12.7)	0.1126
CD4 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD4 <sup>+</sup> LAG-3 <sup>+</sup> high	PF	7.2±1.4 vs 7.3±1.1 (5.0-8.4)	0.4585	9.6±2.5 vs 10.9±1.1 (8.2-12.7)	0.7886
CD4 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD4 <sup>+</sup> TIM-3 <sup>+</sup> high	PF	8.1±1.1 vs 5.0±1.3 (4.9-8.4)	0.1047	11.9±1.2 vs 9.1±2.1 (8.4-12.9)	0.5417
CD8 <sup>+</sup> PD-1 <sup>+</sup> low vs CD8 <sup>+</sup> PD-1 <sup>+</sup> high	PF	7.2±1.3 vs 6.8±1.2 (5.3-8.8)	0.6309	9.4±2.0 vs 10.0±1.4 (7.6-11.9)	0.9571
CD8 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD8 <sup>+</sup> LAG-3 <sup>+</sup> high	PF	6.5±1.4 vs 4.8±0.8 (4.1-7.2)	0.2127	11.0±1.8 vs 10.1±1.9 (8.1-13.0)	0.8569
CD8 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD8 <sup>+</sup> TIM-3 <sup>+</sup> high	PF	7.7±1.1 vs 4.3±1.2 (4.31-7.6)	0.0956	11.0±1.6 vs 9.7±1.6 (8.2-12.3)	0.5441
CD3 <sup>+</sup> CD8 <sup>+</sup> low vs CD3 <sup>+</sup> CD8 <sup>+</sup> high	PT	7.4±1.0 vs 8.0±1.3 (6.1-9.2)	0.8624	9.6±1.4 vs 10.3±1.3 (8.3-11.9)	0.9594
Treg low vs Treg high	PT	9.1±1.8 vs 4.7±1.4 (6.1-9.3)	<b>0.0172</b>	12.1±1.2 vs 7.6±1.0 (8.3-11.9)	<b>0.0046</b>
M2 low vs M2 high	PT	7.6±1.7 vs 8.8±1.1 (6.4-10.2)	0.8228	10.4±1.4 vs 9.3±1.2 (8.1-11.7)	0.4016
Gr-MDSC low vs Gr-MDSC high	PT	9.1±1.1 vs 5.6±1.0 (5.9-9.2)	<b>0.0427</b>	11.3±1.3 vs 7.5±1.1 (7.6-11.2)	<b>0.037</b>
Mo-MDSC low vs Mo-MDSC high	PT	11.2±1.2 vs 7.3±1.4 (7.7-11.5)	<b>0.0178</b>	11.1±1.7 vs 8.0±1.0 (8.1-11.4)	<b>0.026</b>
CD4 <sup>+</sup> PD-1 <sup>+</sup> low vs CD4 <sup>+</sup> PD-1 <sup>+</sup> high	PT	7.9±1.0 vs 7.9±1.7 (6.2-9.5)	0.6616	11.4±1.1 vs 8.3±1.1 (8.5-11.8)	<b>0.043</b>
CD4 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD4 <sup>+</sup> LAG-3 <sup>+</sup> high	PT	8.3±1.1 vs 7.0±1.3 (6.1-9.3)	0.364	11.5±1.4 vs 8.0±0.9 (8.0-11.5)	<b>0.0077</b>
CD4 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD4 <sup>+</sup> TIM-3 <sup>+</sup> high	PT	6.8±1.6 vs 8.4±0.9 (6.1-9.4)	0.7595	11.7±1.2 vs 7.8±1.2 (8.0-11.7)	<b>0.044</b>
CD8 <sup>+</sup> PD-1 <sup>+</sup> low vs CD8 <sup>+</sup> PD-1 <sup>+</sup> high	PT	7.8±1.3 vs 7.9±1.2 (6.2-9.5)	0.9333	10.3±1.3 vs 10.0±1.2 (8.4-11.8)	0.9315
CD8 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD8 <sup>+</sup> LAG-3 <sup>+</sup> high	PT	6.7±1.3 vs 8.0±1.1 (5.7-9.0)	0.6298	9.7±1.5 vs 10.6±1.1 (8.3-11.9)	0.9219
CD8 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD8 <sup>+</sup> TIM-3 <sup>+</sup> high	PT	6.8±1.7 vs 8.4±0.8 (6.1-9.3)	0.7423	8.5±1.6 vs 10.6±1.2 (8.0-11.6)	0.574

The median values of CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes, Treg, M2-macrophages, Gr-MDSC, Mo-MDSC, CD4<sup>+</sup>PD-1<sup>+</sup>, CD4<sup>+</sup>LAG-3<sup>+</sup>, CD4<sup>+</sup>TIM-3<sup>+</sup>, CD8<sup>+</sup>PD-1<sup>+</sup>, CD8<sup>+</sup>LAG-3<sup>+</sup>, CD8<sup>+</sup>TIM-3<sup>+</sup> cells was calculated in pleural fluid (PF; n=49) and pleural tissue (PT; n=33). Patients were classified as “low” or “high” if the percentage of each population was low or equal/higher than the median value. Progression free survival (PFS) and overall survival (OS) probability were calculated using the Kaplan-Meier method, and expressed as mean±SD (months). CI: confidence interval. Significant values are indicated by bold characters.

**Supplemental materials**

**Supplemental data 1. Supplemental Figure 1.tif**

**Supplemental data 2. Supplemental Table 1.docx**

**Supplemental data 3. Supplemental Table 2.docx**

**Supplemental data 4. Supplemental Figure 2.tif**

**Supplemental data 5. Supplemental Figure 3.tif**

**Supplemental data 6. Supplemental Figure 4.tif**


**Supplemental data 7. Supplemental Figure 5.tif**

**Supplemental data 8. Supplemental Figure 6.tif**


**Supplemental data 9. Supplemental Figure 7.tif**

**Supplemental data 10. Supplemental Figure 8.tif**


## Figure 1




## Figure 2




## Figure 3



## Figure 4



# Figure 5






[Click here to access/download](#)

**Supplemental Digital Content**

Supplemental Materials\_JTO R1\_revised version.docx





Click here to access/download  
**Supplemental Digital Content**  
Figure S1\_R1.tif





Click here to access/download  
**Supplemental Digital Content**  
Figure S2\_R1.tif





Click here to access/download  
**Supplemental Digital Content**  
Figure S3\_R1.tif





Click here to access/download  
**Supplemental Digital Content**  
Figure S4\_R1.tif





Click here to access/download  
**Supplemental Digital Content**  
Figure S5\_R1.tif





Click here to access/download  
**Supplemental Digital Content**  
Figure S6\_R1.tif






Click here to access/download  
**Supplemental Digital Content**  
Figure S7\_R1.tif





Click here to access/download  
**Supplemental Digital Content**  
Figure S8\_R1.tif



## **Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma**

Iris C. Salaroglio <sup>a,\*</sup>, Joanna Kopecka <sup>a,\*</sup>, Francesca Napoli <sup>b</sup>, Monica Pradotto <sup>c</sup>, Francesca Maletta <sup>a,d</sup>, Lorena Costardi <sup>e</sup>, Matteo Gagliasso <sup>f</sup>, Vladan Milosevic <sup>a</sup>, Preeta Ananthanarayanan <sup>a</sup>, Paolo Bironzo <sup>a,c</sup>, Fabrizio Tabbò <sup>a,c</sup>, Carlotta F. Cartia <sup>f</sup>, Erika Passone <sup>e</sup>, Valentina Comunanza <sup>a,g</sup>, Francesco Ardissoni <sup>f</sup>, Enrico Ruffini <sup>e</sup>, Federico Bussolino <sup>a,g</sup>, Luisella Righi <sup>a,b</sup>, Silvia Novello <sup>a,c</sup>, Massimo Di Maio <sup>a,h</sup>, Mauro Papotti <sup>a,d</sup>, Giorgio V. Scagliotti <sup>a,c</sup>, Chiara Riganti <sup>a,i</sup>

<sup>a</sup> Department of Oncology, University of Torino, Via Santena 5/bis, 10126, Torino, Italy

<sup>b</sup> Pathology Unit, Department of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Italy

<sup>c</sup> Thoracic Oncology Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, Regione Gonzole 10, University of Torino Regione Gonzole 10, 10043, Orbassano, Italy

<sup>d</sup> Pathology Unit, Department of Oncology at AOU Città della Salute e della Scienza, Corso Bramante 88, 10126, Torino

<sup>e</sup> Thoracic Surgery Unit, Department of Surgery, AOU Città della Salute e Della Scienza, University of Torino, Corso Bramante 88, 10126, Torino

<sup>f</sup> Thoracic Surgery Unit, Department of Oncology at San Luigi Hospital, University of Torino, Regione Gonzole 10, 10043, Orbassano, Italy

<sup>g</sup> Candiolo Cancer Institute - FPO IRCCS, Candiolo, Department of Oncology, University of Torino, SP142, 95, 10060 Candiolo, Italy

<sup>h</sup> Medical Oncology Division, Department of Oncology at AOU Ordine Mauriziano di Torino, Corso Re Umberto 109, 10128, Torino, Italy

<sup>i</sup> Interdepartmental Center “G. Scansetti” for the Study of Asbestos and Other Toxic Particulates, University of Torino, via Pietro Giuria 5, 10126, Italy

\* Equal contribution

**Corresponding author:** Dr. Chiara Riganti, Department of Oncology, University of Torino, via Santena 5/bis, 10126, Torino, Italy; phone: +390116705857; fax: +390116705845; email: [chiara.riganti@unito.it](mailto:chiara.riganti@unito.it)

#### **Conflicts of interest statement**

Silvia Novello received honoraria for speaker bureau and advisory role from Astrazeneca, BI, Roche, Pfizer, MSD, Eli Lilly, Abbvie, Celgene for activities unrelated to the present study.

Giorgio Scagliotti received honoraria for speaker bureau and advisory role from Astrazeneca, Roche, Pfizer, MSD, Eli Lilly, Abbvie and travel support from MSD and Bayer for activities unrelated to the present study.

The other authors have no conflict of interests

1 **Potential diagnostic and prognostic role of micro-environment in malignant pleural**  
2 **mesothelioma**

3

4 Iris C. Salaroglio <sup>a,\*</sup>, Joanna Kopecka <sup>a,\*</sup>, Francesca Napoli <sup>b</sup>, Monica Pradotto <sup>c</sup>, Francesca  
5 Maletta <sup>a,d</sup>, Lorena Costardi <sup>e</sup>, Matteo Gagliasso <sup>f</sup>, Vladan Milosevic <sup>a</sup>, Preeta  
6 Ananthanarayanan <sup>a</sup>, Paolo Bironzo <sup>a,c</sup>, Fabrizio Tabbò <sup>a,c</sup>, Carlotta F. Cartia <sup>f</sup>, Erika Passone <sup>e</sup>,  
7 Valentina Comunanza <sup>a,g</sup>, Francesco Ardissonne <sup>f</sup>, Enrico Ruffini <sup>e</sup>, Federico Bussolino <sup>a,g</sup>,  
8 Luisella Righi <sup>a,b</sup>, Silvia Novello <sup>a,c</sup>, Massimo Di Maio <sup>a,h</sup>, Mauro Papotti <sup>a,d</sup>, Giorgio V.  
9 Scagliotti <sup>a,c</sup>, Chiara Riganti <sup>a,i</sup>

10

11 <sup>a</sup> Department of Oncology, University of Torino, Via Santena 5/bis, 10126, Torino, Italy

12 <sup>b</sup> Pathology Unit, Department of Oncology at San Luigi Hospital, University of Torino,  
13 Regione Gonzole 10, 10043, Orbassano, Italy

14 <sup>c</sup> Thoracic Oncology Unit and Medical Oncology Division, Department of Oncology at San  
15 Luigi Hospital, Regione Gonzole 10, University of Torino Regione Gonzole 10, 10043,  
16 Orbassano, Italy

17 <sup>d</sup> Pathology Unit, Department of Oncology at AOU Città della Salute e della Scienza, Corso  
18 Bramante 88, 10126, Torino

19 <sup>e</sup> Thoracic Surgery Unit, Department of Surgery, AOU Città della Salute e Della Scienza,  
20 University of Torino, Corso Bramante 88, 10126, Torino

21 <sup>f</sup> Thoracic Surgery Unit, Department of Oncology at San Luigi Hospital, University of Torino,  
22 Regione Gonzole 10, 10043, Orbassano, Italy

23 <sup>g</sup> Candiolo Cancer Institute - FPO IRCCS, Candiolo, Department of Oncology, University of  
24 Torino, SP142, 95, 10060 Candiolo, Italy

1 <sup>h</sup> Medical Oncology Division, Department of Oncology at AOU Ordine Mauriziano di Torino,  
2 Corso Re Umberto 109, 10128, Torino, Italy

3 <sup>i</sup> Interdepartmental Center “G. Scansetti” for the Study of Asbestos and Other Toxic  
4 Particulates, University of Torino, via Pietro Giuria 5, 10126, Italy

5

6 \* Equal contribution

7 **Corresponding author:** Dr. Chiara Riganti, Department of Oncology, University of Torino,  
8 via Santena 5/bis, 10126, Torino, Italy; phone: +390116705857; fax: +390116705845; email:  
9 [chiara.riganti@unito.it](mailto:chiara.riganti@unito.it)

10

#### 11 **Conflicts of interest statement**

12 **Silvia Novello received honoraria for speaker bureau and advisory role from Astrazeneca, BI,**  
13 **Roche, Pfizer, MSD, Eli Lilly, Abbvie, Celgene for activities unrelated to the present study.**

14 **Giorgio Scagliotti received honoraria for speaker bureau and advisory role from Astrazeneca,**  
15 **Roche, Pfizer, MSD, Eli Lilly, Abbvie and travel support from MSD and Bayer for activities**  
16 **unrelated to the present study.**

17 **The other authors have no conflict of interests**

18

#### 19 **Abstract**

20 **Introduction.** A comprehensive analysis of the immune-cell infiltrate collected from pleural  
21 fluid and from biopsies of malignant pleural mesothelioma (MPM) may contribute to  
22 understand the immune-evasion mechanisms related to tumor progression, aiding in  
23 differential diagnosis and potential prognostic stratification. Till now such approach has not  
24 routinely been verified.

1 **Methods.** We enrolled in 275 patients with an initial clinical diagnosis of pleural effusion.  
2 Specimens of pleural fluids and pleural biopsies used for the pathological diagnosis and the  
3 immune-phenotype analyses were blindly investigated by multi-parametric flow cytometry.  
4 The results were analyzed by Kruskal-Wallis test. The Kaplan-Meier and log-rank tests were  
5 used to correlate immune-phenotype data with patients' outcome.

6 **Results.** The cut-offs of intra-tumor T-regulatory (Treg; >1.1%) cells, M2-macrophages  
7 (>36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; >5.1% and  
8 4.2%, respectively), CD4<sup>+</sup>PD1<sup>+</sup> (>5.2%) and CD8<sup>+</sup>PD1<sup>+</sup> (6.4%) cells, CD4<sup>+</sup>LAG-3<sup>+</sup> (>2.8% )  
9 and CD8<sup>+</sup>LAG-3<sup>+</sup> (>2.8%) cells, CD4<sup>+</sup>TIM-3<sup>+</sup> (>2.5%) and CD8<sup>+</sup>TIM-3<sup>+</sup> (>2.6%) cells  
10 discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. The presence of  
11 intra-tumor MDSC contributed to the anergy of tumor-infiltrating lymphocytes (TILs). The  
12 immune-phenotype of pleural fluid cells had no prognostic significance. By contrast, the intra-  
13 tumor Treg and MDSC levels significantly correlated with progression-free and overall  
14 survival, the PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> CD4<sup>+</sup>TILs correlated with overall survival.

15 **Conclusions.** A clear immune-signature of pleural fluids and tissues of MPM patients may  
16 contribute to better predict patients' outcome.

17

18 **Key words:** malignant pleural mesothelioma; tumor-infiltrating lymphocytes; T-regulatory  
19 cells; myeloid-derived suppressor cells; immune checkpoints

20

## 21 **Abbreviations:**

22 DCFDA-AM: 5-(and-6)-chloromethyl-2',7'-dichlorodihydro-fluorescein diacetate-  
23 acetoxymethyl ester; FBS: fetal bovine serum; Gr-MDSC: granulocytic myeloid-derived  
24 suppressor cells; HR: hazard ratio; IDO: 2,3-indoleamine dioxygenase; Mo-MDSC: monocytic  
25 myeloid-derived suppressor cells; MPM: malignant pleural mesothelioma; MTS: metastases;

- 1 OS: overall survival; PFS: progression free survival; NK: natural killer; NO: nitric oxide; ROS:
- 2 reactive oxygen species; TAM: tumor-associated macrophage; Treg: T-regulatory; TIL: tumor-
- 3 infiltrating lymphocyte.

## 1 Introduction

2 Malignant pleural mesothelioma (MPM) is an asbestos-related cancer characterized by a long  
3 latency.<sup>1</sup> It has a low mutational burden and the tumor micro-environment rather than the  
4 genetic abnormalities in mesothelial cells may contribute to MPM development and  
5 progression.<sup>2</sup> The MPM micro-environment is rich of immune-suppressive and anergic  
6 immune cells,<sup>4-6</sup> such as T-regulatory (Treg),<sup>7-8</sup> granulocytic and monocytic myeloid-derived  
7 suppressor cells (Gr-MDSC/Mo-MDSC)<sup>5,7</sup> and M2-polarized tumor associated macrophages  
8 (TAMs),<sup>9</sup> that – together with soluble factors, such as cytokines, chemokines<sup>7</sup> and kynurenine,  
9 the product of 2,3-indoleamine dioxygenase (IDO) enzyme<sup>8</sup> – lead to a poor response to  
10 immune-therapy.<sup>10</sup>

11 Several cytokines accumulated in the pleural effusion of MPM patients promote the M2  
12 polarization of macrophages.<sup>11,12</sup> M2/M3-macrophages and<sup>11,13</sup> Gr-MDSC<sup>5</sup> of MPM patients,  
13 as well as MPM cells<sup>14</sup> reduce the proliferation of heterologous CD8<sup>+</sup>T-lymphocytes, by  
14 producing immune-suppressive mediators such as reactive oxygen species (ROS), nitric oxide  
15 (NO) and kynurenine.<sup>5,8,15</sup> MDSC are killed by active CD8<sup>+</sup>T-lymphocytes,<sup>16,17</sup> while either  
16 Treg and MDSC reduce CD8<sup>+</sup>T-lymphocytes activity<sup>5,7,18</sup> and memory CD8<sup>+</sup>T-lymphocytes  
17 recruitment,<sup>19</sup> inducing a vicious immune-suppressive circle.

18 The high expression of immune-checkpoints on T-lymphocytes and of their ligands on MPM  
19 cell has another crucial role in the MPM-induced anergy of tumor-infiltrating lymphocytes  
20 (TILs).<sup>6</sup> The PD-1/PD-L1 axis is the more extensively studied and the most correlated with  
21 early progression and shorter survival.<sup>3,4,20,21,22,23</sup> LAG-3 and TIM-3 have been detected on  
22 CD4<sup>+</sup> and CD8<sup>+</sup>TILs<sup>24</sup> or in formalin-fixed paraffin embedded samples.<sup>25</sup> Despite the high  
23 inter-patient and intra-sample variability,<sup>26</sup> both LAG-3 and TIM-3 contribute to the functional  
24 exhaustion of TILs. Furthermore CTLA-4 has been investigated as a potential therapeutic target  
25 in MPM, but the CTLA-4 inhibitor Tremelimumab did not show higher efficacy than placebo

1 in a double blind phase 2 trial,<sup>27</sup> raising concerns about the role of this immune-checkpoint in  
2 the MPM-induced immune-suppression.

3 The dissection of the immune-environment of MPM is quite difficult and has often twisted  
4 conflicting findings for different reasons. For instance, the number of T-cells and macrophages  
5 detected in pleural effusion not always mirrors the amount of the same cells infiltrating MPM  
6 tissue.<sup>28</sup> Some studies reported the same immune-signature in the MPM pleural effusion and  
7 in the peripheral blood,<sup>24</sup> while others did not,<sup>5</sup> raising concerns about peripheral blood as a  
8 biological surrogate that reliably reproduces the MPM immune-environment. Indeed, immune  
9 cells can be continuously exchanged between pleural cavity and tumor tissue, and/or between  
10 peripheral blood and pleural environment. This dynamic immune-environment leads to an  
11 inhomogeneous distribution of immune-cells within MPM tissue. Moreover, the immune-  
12 environment is exposed to time-changes related to the natural tumor progression and/or to  
13 chemotherapy-related effects.<sup>28</sup> Also qualitative and quantitative changes in tumor/stroma ratio  
14 may produce a dramatic rewiring in the MPM-infiltrating immune cell subsets.<sup>18</sup> The high  
15 intra-patient variability, the intra-tumor heterogeneity,<sup>29</sup> the different timing of analysis may  
16 partially justify the divergent results.

17 A simultaneous analysis of all the immune-populations detectable in the pleural effusion and  
18 infiltrating the tissue has never been performed. The present study aims at a comprehensive  
19 analysis of the immune-infiltrate detected in the pleural fluid and in the biopsies of pleural  
20 tissue, collected during routine diagnostic procedures from patients with pleural effusions of  
21 unknown origin, in order to identify an immune-phenotype with diagnostic and prognostic  
22 value in MPM patients.

## 23 **Materials and methods**

24 **Samples collection.** From June 2016 through June 2018 we enrolled 275 patients with an initial  
25 clinical diagnosis of pleural effusion of unknown origin. The enrollment of patients was

1 stopped when we have reached the sample size with an adequate power in the MPM patient  
2 cohort (see “Statistical analysis” paragraph). Samples were obtained during diagnostic  
3 thorascopies, at the Thoracic Surgery Division of San Luigi Gonzaga Hospital, Orbassano,  
4 and AOU Città della Salute e della Scienza, Torino, Italy. Two aliquots of pleural fluid and  
5 pleural tissue were collected by thoracic surgeons at the same time for each patient. Each  
6 sample was managed by the Pathology Unit of the two Institutions: one aliquot was used for  
7 diagnostic purposes according to local pathology guidelines, the second one was used for the  
8 research study here reported. In case of limited volume of pleural fluid or limited dimension of  
9 pleural tissue, both aliquots were dedicated to the diagnostic workup. In accordance with this  
10 criterion, 183 pleural fluids and 119 pleural biopsies were available for the research study.  
11 Within all these samples, 63 pathologically diagnosed non-malignant pleuritis, 49 MPM and  
12 32 pleural metastases - MTS - of malignant tumors for pleural fluid; 16 non-malignant pleuritis,  
13 33 MPM and 5 MTS for pleural tissue biopsies met the technical inclusion criteria (see  
14 “Phenotyping of immune cells” paragraph) and were analyzed in this study. 9 patients with  
15 pathologically diagnosed pleuritis and 20 patients with pathologically diagnosed MPM had  
16 both pleural fluid and pleural tissue available for the study. The flow chart of sample collection  
17 and processing is reported in the **Supplemental Figure 1**. The characteristics of samples used  
18 for the immune-phenotyping in the present study are reported in the **Supplemental Table 1**.  
19 The anonymized patients’ history (asbestos exposure and smoking status, whenever available),  
20 the pathological diagnosis and the clinical follow-up (progression free survival, PFS; overall  
21 survival, OS) of MPM patients, performed at the Thoracic Oncology Unit, San Luigi Gonzaga  
22 Hospital, are reported in the **Supplemental Table 2**. All patients with MPM were in advanced  
23 clinical stage and all were treated with standard cytotoxic chemotherapy according to current  
24 guidelines.<sup>30</sup> The researchers performing the immune-phenotyping analyses reported below  
25 worked in a blind manner, being unaware of the pathological diagnosis at the time of the assays.

1 **The association between pathological diagnosis, immune-phenotype analysis was performed**  
2 **during the final data analysis.** The Ethics Committee of San Luigi Gonzaga Hospital,  
3 Orbassano, Italy approved the study (#126/2016).

4 **Sample processing and mesothelial/tumor histological analysis.** 50 ml of pleural fluid were  
5 centrifuged at 1200×g for 5 min, washed in PBS containing 1 mg/ml ciprofloxacin (Sigma  
6 Chemicals Co., St. Louis, MO), and re-suspended at  $1 \times 10^6$  cells/ml in Ham's F10 nutrient  
7 mixture medium (Invitrogen Life Technology, Milano, Italy), supplemented with 10% v/v fetal  
8 bovine serum (FBS; Sigma Chemicals Co.), 1% v/v penicillin-streptomycin (Sigma Chemicals  
9 Co.). Tissues were digested in medium containing 1 mg/ml collagenase and 0.2 mg/ml  
10 hyaluronidase (Sigma Chemicals Co.) for 1 h at 37°C. Cells from pleural fluid and digested  
11 tissue were seeded in culture flasks (Becton Dickinson, Franklin Lakes, NJ) for 24 h in  
12 complete medium. After this period, the cells floating in the supernatant, i.e. immune cells in  
13 the pleural fluid or infiltrating the tissue, were collected, counted and analyzed for their  
14 immune-phenotype as detailed below. Adherent cells were analyzed for their  
15 mesothelial/tumor origin: after detaching by gentle scraping, cells were centrifuged at 1200×g  
16 for 5 min, fixed in 4% v/v formalin at 4 °C overnight and stained with the following antibodies:  
17 calretinin (Thermo Fisher Scientific, Waltham, MA), Wilms tumor-1 antigen (Thermo Fisher  
18 Scientific), cytokeratin 5 (Menarini Diagnostics, Bagno a Ripoli, Italy), podoplanin (Dako,  
19 Santa Clara, CA), pancytokeratin (Dako), epithelial membrane antigen (EMA, Dako), carcino-  
20 embryonic antigen (CEA, Dako), using an automated immunostainer (Benchmark Ventana  
21 Medical Systems, Tucson, AZ).

22 **Phenotyping of immune cells.** From all the samples **available for research purpose, only**  
23 **samples with  $\geq 1 \times 10^6$  viable (i.e. Trypan-blue negative) cells in the supernatants or adherent**  
24 **in flask were included in the analysis. Preliminary set-up experiments indicated that  $\geq 1 \times 10^6$**   
25 **viable cells was the minimal number required allowing to acquire  $1 \times 10^5$  cells/staining, in order**

1 to perform the whole set of the immune-phenotyping tests on each sample. Samples with  $\leq$   
2  $1 \times 10^6$  viable cells were excluded, since they did not allow to acquire  $1 \times 10^5$  cells/staining. The  
3 supernatants were centrifuged at  $1200 \times g$  for 5 min, the pellet was washed in PBS and re-  
4 suspended in PBS containing 5% v/v FBS. A three- and four-color flow cytometry was  
5 performed, with the appropriate combinations of antibodies (all diluted 1:10, from Miltenyi  
6 Biotec, Teterow, Germany if not otherwise specified) against: CD3 (mouse clone REA613),  
7 CD4 (mouse clone M-T466), CD8 (mouse clone BW135/80) for T-lymphocytes; CD25 (mouse  
8 clone 4E3), CD127 (mouse clone MB1518C9) for Treg cells; CD56 (mouse clone AF127H3),  
9 CD335/NKp46 (mouse clone 9E2) for natural killer (NK) cells; CD19 (mouse clone REA675)  
10 for B-lymphocytes; CD14 (mouse clone TÜK4) and CD68 (mouse clone Y1/82A) for  
11 monocytes and macrophages; CD68 (mouse clone Y1/82A), CD208 (mouse clone DCN228)  
12 and Arginase-1 (sheep polyclonal, # IC5868A, R&D Biosystems; Minneapolis, MN) for M2-  
13 polarized macrophages; CD68 (mouse clone Y1/82A), CD86 (mouse, clone FM95) and iNOS  
14 (rabbit polyclonal, #SPC-1325, StressMark Biosciences Inc., Victoria, Canada) for M1-  
15 polarized macrophages; CD11b (rat clone M1/70.15.11.5), CD14 (mouse clone TÜK4), CD15  
16 (mouse clone VIMC6) for granulocytic myeloid-derived suppressor cells (Gr-MSDC) and  
17 monocytic myeloid-derived suppressor cells (Mo-MDSC). In each combination staining,  $1 \times 10^5$   
18 cells were analyzed using a Guava® easyCyte flow cytometer (Millipore, Bedford, MA),  
19 equipped with the InCyte software.

20 **Expression of immune-checkpoints and immune-checkpoint ligands.** CD3<sup>+</sup> cells were  
21 isolated from  $1 \times 10^6$  immune cells of the supernatant of each culture with the Pan T Cell  
22 Isolation Kit (Miltenyi Biotec.), washed and re-suspended in PBS containing 5% v/v FBS. The  
23 detection of immune-checkpoints on CD3<sup>+</sup> T-lymphocytes and/or immune-checkpoint ligands  
24 on MPM cells were performed using antibodies for CD279/PD-1 (mouse clone PD1.3.1.3),  
25 CD223/LAG-3 (clone REA351), CD366/TIM-3 (mouse clone F38-2E2), CD152/CTLA-4

1 (mouse clone BNI3; all diluted 1:10, Miltenyi Biotec.), CD274/**PD-1L** (1:100, mouse clone  
2 29E.2A3, BioLegend, San Diego, CA), anti-GAL-9 (mouse, clone 9M1-3, BioLegend). **In each**  
3 **combination staining**  $1 \times 10^5$  cells were analyzed using a Guava® EasyCyte flow cytometer  
4 (Millipore), equipped with the InCyte software.

5 **MDSC functional properties.** **ROS** were measured using the fluorescent probe 5-(and-6)-  
6 chloromethyl-2',7'-dichlorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-AM),  
7 as previously reported.<sup>31</sup> The levels of nitrite, the stable derivative of **NO**, in cell culture  
8 supernatants were measured by the Griess method.<sup>32</sup> The amount of kynurenine was assessed  
9 by spectrophotometry.<sup>33</sup> The results were expressed as nmoles/mg cellular proteins.

10 **Proliferation and activation of T-lymphocytes co-cultured with MDSC.**  $1 \times 10^4$  sorted intra-  
11 tissue Gr-MDSC and Mo-MDSC were co-cultured for 6 days at a 1:1 ratio with sorted intra-  
12 tissue  $CD3^+CD8^+$ T-cytotoxic lymphocytes, either autologous or heterologous, as detailed in  
13 the experimental section, in the presence of anti-CD3/anti-CD28 dynabeads (Invitrogen Life  
14 Technologies) to activate lymphocytes. The proliferation of T-lymphocytes was assessed by  
15 adding 1  $\mu$ Ci of [<sup>3</sup>H]thymidine (PerkinElmer, Waltham, MA) 18 h before the end of the co-  
16 cultures, then harvesting the plates and counting the radioactivity by liquid scintillation count.  
17 The results were expressed as count per minute (cpm). The percentage of  $CD8^+CD107a^+$  and  
18 the production of IFN- $\gamma$ , considered indexes of activated cytotoxic T-lymphocytes, were  
19 measured by flow cytometry and ELISA, as reported.<sup>14</sup>

20 **Statistical analysis.** **Before starting the enrollment of patients, the requested number of**  
21 **patients in the MPM cohort was calculated using the G\*Power Software ([www.gpower.hhu.de](http://www.gpower.hhu.de))**  
22 **using the following assumptions: significance level ( $\alpha$  error probability)  $\leq 0.05$ , power (1- $\beta$**   
23 **error probability) = 0.80, effect size  $\rho = 0.40$ ). With these parameters, the sample size required**  
24 **was  $34 \pm 2$  MPM.**

1 The normality distribution of each parameter analyzed was checked with the D'Agostino and  
2 Pearson test. All parameters had a Gaussian distribution or approximation. However, the results  
3 were conservatively analyzed by the non-parametric Kruskal-Wallis test (GraphPad PRISM  
4 6.0 software). All data in the figures are provided as means±SD. Medians and quartile values  
5 are reported in the figure legends. In order to partially correct for the multiplicity of tests  
6 performed, a conservative  $p < 0.01$  was considered statistically significant. For each parameter  
7 specific cut-off discriminating MPM from pleuritis were calculated in order to have a 100%  
8 sensitivity (0% false negative) and >89% specificity (<11% false positive). To correlate the  
9 immune-parameters with PFS and OS, since there are no previously reported and validated cut-  
10 off values for the immune-phenotypic parameters analyzed, patients were exploratively divided  
11 into “low expressing” and “highly expressing” groups, if their value was below or equal/above  
12 the median value. The Kaplan-Meier method was used to calculate PFS and OS. Log rank test  
13 was used to compare the outcome of each group as hazard ratio (HR, i.e. risk of patient death).  
14 Considering the exploratory nature of the survival analysis, no adjustment for multiplicity was  
15 made, and  $p < 0.05$  was considered statistically significant.

## 16 **Results**

### 17 **High T-regulatory cells/high myeloid-derived suppressor cells discriminate malignant** 18 **pleural mesothelioma from inflammatory pleuritis and secondary pleural tumors**

19 CD3<sup>+</sup>T-lymphocytes represented the prevalent immune population within pleural fluid or  
20 pleural tissue, without differences between samples of pleuritis, MPM or MTS (**Figure 1A**).  
21 CD3<sup>+</sup>CD4<sup>+</sup>T-helper lymphocytes were up to 60% in all the samples, without differences  
22 between patient subgroups (**Figure 1B**). CD3<sup>+</sup>CD8<sup>+</sup>T-cytotoxic lymphocytes, representing  
23 approximately 5% of immune cells in pleural fluids from pleuritis, significantly increased in  
24 MPM and MTS-pleural fluid samples. By contrast they represented up to 50% of TILs in  
25 pleuritis and significantly decreased in MPM and MTS (**Figure 1C**). This trend allowed to

1 discriminate pleuritis (all with CD3<sup>+</sup>CD8<sup>+</sup>cells <6.3% in pleural fluid) from MPM (all with  
2 CD3<sup>+</sup>CD8<sup>+</sup>cells >25% in pleural fluid) (**Figure 1D**). T-reg cells were significantly higher in  
3 both pleural fluid and tissue from MPM patients compared to pleuritis and MTS-derived  
4 samples (**Figure 1E**). A cut-off of >1.4% in pleural fluid and >1.1% in pleural tissue Treg cells  
5 identified 100% (20/20) MPM and excluded 88.8% (8/9) pleuritis (**Figure 1F**). NK and B-  
6 lymphocytes were poorly represented and did not show any differences among groups  
7 (**Supplemental Figure 2A-B**).

8 Also monocytes did not differ (**Supplemental Figure 3**), while pleural fluid and tissue  
9 macrophages were significantly higher in MPM and MTS-derived samples (**Figure 2A**). All  
10 pleuritic samples had <34% macrophages in pleural fluid and <35% in tissue while all MPM  
11 samples were above these thresholds (**Figure 2B**). More relevantly the pro-tumorigenic M2-  
12 macrophages were higher in MPM and MTS compared to pleuritis (**Figure 2C**). According to  
13 these parameters, a clear separation between pleuritis (100% of patients with M2-macrophages  
14 <29% in pleural fluid and <36% in pleural tissue) and MPM (100% of patients with M2-  
15 macrophages >41% in pleural fluid and >44% in pleural tissue) was clearly identified (**Figure**  
16 **2D**). Anti-tumorigenic M1-macrophages were lower in both pleural fluid and tissue of MPM  
17 and MTS compared with pleuritis (**Supplemental Figure 4**).

18 A significantly higher number of Gr-MDSC (**Figure 2E**) and Mo-MDSC (**Figure 2G**) in  
19 pleural fluid and tissue was detected in MPM compared to pleuritis and MTS. A clear threshold  
20 of 5.1% Gr-MDSC in both pleural fluid and tissue discriminated 100% pleuritis from 100%  
21 MPM (**Figure 2F**). A cut-off of >3.6% Mo-MDSC in pleural fluid and >4.2% in pleural tissue  
22 identified 100% MPM and excluded 88.8% pleuritis (**Figure 2H**).

### 23 **The intratumor myeloid-derived suppressor cells determine T-lymphocytes anergy**

24 The MDSC isolated from MPM tissue showed increased production of ROS (**Figure 3A**), NO  
25 (**Figure 3B**) and kynurenine (**Figure 3C**), compared to those obtained from tissue biopsies of

1 other subgroups. In co-culture with CD8<sup>+</sup>T-cytotoxic lymphocytes from the tissue of the same  
2 patient, both Gr-MDSC and Mo-MDSC derived from MPM reduced CD8<sup>+</sup>T-lymphocytes  
3 proliferation (**Figure 3D**), CD107a positivity (**Figure 3E**) and IFN- $\gamma$  production (**Figure 3F**),  
4 compared to the autologous CD8<sup>+</sup>T-lymphocytes/MDSC-co-cultures derived from the pleuritis  
5 and MTS subgroups. The immune-suppressive properties of either Gr-MDSC and Mo-MDSC  
6 were further demonstrated by co-incubating **Gr-MDSC and Mo-MDSC derived from MPM**  
7 **tissue** with heterologous T-lymphocytes derived from patients with pleuritis. In this setting,  
8 **proliferation, CD107a positivity and IFN- $\gamma$  production of T-lymphocytes derived from pleuritis**  
9 **was reduced to the same level of T-lymphocytes derived from MPM (Figure 3D-F).**

#### 10 **A high number of intra-tumor PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> infiltrating lymphocytes is peculiar** 11 **of malignant pleural mesothelioma**

12 The immune-checkpoints PD-1 (**Figure 4A-B**), LAG-3 (**Figure 4C-D**) and TIM-3 (**Figure 4E-**  
13 **F**) were higher on CD4<sup>+</sup>T-helper and CD8<sup>+</sup>T-cytotoxic lymphocytes of MPM compared to the  
14 lymphocytes from pleuritis **and MTS**, either in pleural fluid and in pleural tissue. The cut-off  
15 values of 6.7% **in pleural fluid**, 5.2% **in pleural tissue** for CD4<sup>+</sup>PD1<sup>+</sup> (**Supplemental Figure**  
16 **5A**), 6.3% **in pleural fluid**, 6.4% **in pleural tissue** for CD8<sup>+</sup>PD1<sup>+</sup>cells (**Supplemental Figure**  
17 **5B**), 4.9% **in pleural fluid**, 2.8% **in pleural tissue** for CD4<sup>+</sup>LAG-3<sup>+</sup> (**Supplemental Figure 5C**),  
18 5.2% **in pleural fluid**, 2.8% **in pleural tissue** for CD8<sup>+</sup>LAG-3<sup>+</sup>cells (**Supplemental Figure 5D**),  
19 1.9% **in pleural fluid**, 2.5% **in pleural tissue** for CD4<sup>+</sup>TIM-3<sup>+</sup> (**Supplemental Figure 5E**), 2.4%  
20 **in pleural fluid**, 2.6% **in pleural** for CD8<sup>+</sup>TIM-3<sup>+</sup>cells **tissue (Supplemental Figure 5F)**,  
21 discriminated 100% MPM from pleuritis. In our series, the lymphocytic expression of CTLA-  
22 4 did not differ between each subgroup (**Figure 4G-H**).

23 The higher expression of immune-checkpoints on T-lymphocytes was paralleled by the higher  
24 expression of **PD-L1 (Figure 5A)**, LAG-3 (**Figure 5B**), TIM-3 (**Figure 5C**) and GAL-9

1 (Figure 5D) on MPM cells compared to pleuritis and – for LAG-3 and TIM-3 – compared to  
2 MTS.

### 3 **Specific immune-signatures of intratumor infiltrate have a prognostic value**

4 Furthermore we investigated the potential prognostic role of the immune-phenotypic  
5 parameters that significantly differed between MPM and pleuritis.

6 The amount of CD3<sup>+</sup>CD8<sup>+</sup> cells, Treg, M2-polarized macrophages, Gr/Mo-MDSC, PD-  
7 1<sup>+</sup>/LAG-3<sup>+</sup>/TIM3<sup>+</sup> CD4<sup>+</sup> or CD8<sup>+</sup> cells present in the pleural fluids did not show any significant  
8 correlation with PFS and OS of MPM patients (Table 1). As far as the intratumor immune-  
9 infiltrate was concerned, the amount of CD3<sup>+</sup>CD8<sup>+</sup> cells and M2 were not associated with any  
10 prognostic significance, while high intratumor Treg, Gr-MDSC and Mo-MDSC significantly  
11 correlated with shorter PFS and OS (Table 1; Supplemental Figure 6A-E). The amount of  
12 PD-1<sup>+</sup> and LAG-3<sup>+</sup> CD4<sup>+</sup> cells correlated with a lower OS (Table 1; Supplemental Figure  
13 7A-C). The expression of immune-checkpoints on intratumor CD8<sup>+</sup> had no prognostic  
14 significance (Table 1; Supplemental Figure 8A-C).

### 15 **Discussion**

16 Specific immune-phenotypic markers on tissue microarrays<sup>20</sup> or fine-needle aspirate<sup>24</sup> are  
17 currently investigated to better characterize the immune-environment of MPM. The present  
18 study for the first time assessed a comprehensive and multi-parametric analysis of the immune-  
19 infiltrate of either pleural fluid and pleural tissue, performed parallelly to the routine diagnostic  
20 procedures. Based on flow cytometry assays, our experimental model allows to recover viable  
21 cells, coupling the phenotypic analysis with functional assays of adaptive immunity. Moreover,  
22 we detected a quite robust immune-signature that discriminates MPM from pleuritis and from  
23 pleural metastases secondary to other malignancies. By selecting specific cut-offs for each  
24 immune-parameter analyzed with 100% sensitivity and ≥89% good specificity, we maximized  
25 the possibility to identify correctly all the MPM patients, accepting the possibility to have

1 sporadic cases of pleuritis erroneously identified as MPM. Since all samples were subjected to  
2 the usual pathological diagnosis, the rare cases of pleuritis erroneously identified as MPM on  
3 the basis of immune-phenotype analysis could be easily re-verified by the pathologist and/or  
4 clinically followed-up more strictly . The analysis of the immune-parameters was not intended  
5 to replace the pathological diagnosis but simply to complement the pathological diagnosis of  
6 MPM with a set of immunological tests and potential new prognostic information. Each  
7 parameter was indeed correlated with PFS or OS, exploratively using the median values as cut-  
8 off since in literature there are no previously reported and validated cut-offs for the parameters  
9 analyzed and the identification of the optimal cutoff was beyond the scope of this analysis.

10 The first relevant finding discriminating MPM from non-malignant pleuritis was the higher  
11 intra-pleural fluid CD8<sup>+</sup>T-lymphocytes coupled with the lower intra-pleural CD8<sup>+</sup>TILs. The  
12 amount of CD8<sup>+</sup>TILs has been associated with adverse<sup>18,34</sup> or good<sup>20</sup> prognosis, but in our case  
13 series, we did not detect any prognostic significance. It is likely that - more than the absolute  
14 number of CD8<sup>+</sup>T-lymphocytes - their functional exhaustion, due to the presence of Treg cells  
15 and MDSC,<sup>7,18</sup> is critical in determining tumor progression and patients' outcome.

16 We identified high Treg cells within pleural fluid and tissue as specific biomarkers of MPM  
17 rather than of benign pleural disease or pleural MTS. The high intra-MPM Treg was a negative  
18 prognostic factor, while the amount of Treg in pleural fluid had no clinical significance, as  
19 reported previously.<sup>18</sup> This data pointed out that the intratumor immune-infiltrate – more than  
20 the immune-population in the pleural effusion – in this case is more reliable in predicting the  
21 patients' outcome.

22 As expected, we did not detect significant differences in overall TAMs between MPM and  
23 metastatic patients. Compared to pleuritis, M2-macrophages were increased in both tumor and  
24 pleural fluid of MPM. The correlations between the number of TAMs or the ratio M2/TAM  
25 and the tumor progression or patients' outcomes<sup>9,18,20,34</sup> are highly discordant. According to

1 our data **M2 percentage is not a significant predictor** of patients' outcome but **it is** an immune-  
2 marker highly differentiating MPM from non-malignant conditions, as Gr-MDSC and – to a  
3 lesser extent – Mo-MDSC.

4 In our study, Gr- and Mo-MDSC abrogated proliferation and cytotoxic activity of autologous  
5 TILs **and of TILs derived from patients with pleuritis. These data suggest that MDSC mediate**  
6 **an important role** MPM immune-suppression, **likely by the increased production of ROS, NO**  
7 **and kynurenine.** Again, only the intratumor-infiltrating MDSC - and not the MDSC of pleural  
8 fluid - are significantly associated with poorer PFS and OS. Taking into consideration the  
9 dynamic exchange occurring between pleural fluid and tumor,<sup>28</sup> pleural fluid can be considered  
10 as a reservoir of immune-suppressive cells: higher is their migration from pleural fluid into the  
11 tumor, higher is the chance to characterize an immune-escape status and predict tumor  
12 progression.

13 **Immune-checkpoints expression are other key players of immune-suppression in MPM.** The  
14 immunohistochemical expression of PD-L1 and PD-1 is not always reliable as biomarker in  
15 discriminating pleuritis from MPM: PD-L1 expression was absent in benign lesions, but PD-1  
16 resulted more expressed on TILs of non-tumoral samples than in TILs of MPM analyzed by  
17 immunohistochemistry,<sup>23</sup> a finding contrasting with the high percentage of PD-1<sup>+</sup> cells reported  
18 in MPM using flow cytometry.<sup>3,4,6</sup> The **type of diagnostic** antibody and the abundance of the  
19 immune-infiltrate in the examined sample may explain this discrepancy. **The** multi-parametric  
20 flow cytometry analysis revealed that the amount of PD-1 expressed in CD4<sup>+</sup> and CD8<sup>+</sup>T-  
21 lymphocytes well discriminates MPM from non-malignant pleuritis, but not from metastatic  
22 cancers, in line with the observation that pleural **effusion** from lung cancer are also rich of  
23 PD1<sup>+</sup>CD8<sup>+</sup>T-lymphocytes and PD-L1<sup>+</sup>-cancer cells.<sup>35</sup>

1 Our data indicate that the expression of PD-1, LAG-3 and TIM-3 in TILs, but not in T-cells in  
2 pleural effusion, correlated with lower OS. The lack of correlation between immune-  
3 checkpoint levels and PFS likely suggests that the accumulation of immune-checkpoint-  
4 positive, anergic lymphocytes occurs at advanced stages in MPM patients and determines  
5 prognosis in the terminal stages only. More interestingly, only PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup>CD4<sup>+</sup>  
6 cells, but not CD8<sup>+</sup> cells, were negative prognostic factors. Since CD4<sup>+</sup> T-cells are a hub in the  
7 engagement of other immune populations, we may hypothesize that a loss of function of CD4<sup>+</sup>  
8 T-lymphocytes impairs the immune-recognition of MPM cells more than a dysfunction in the  
9 effector CD8<sup>+</sup> T-cells, leading to faster progression and reduced survival. Among the immune-  
10 checkpoints analyzed in MPM patients, CTLA-4 was poorly expressed on the surface of T-  
11 lymphocytes. This is likely related to the cytosol localization of CTLA-4 and the high recycling  
12 rate.<sup>36</sup> Our data need to be re-assessed when a staining optimization for intracellular CTLA-4  
13 antigen will be achieved.

14 In conclusion, we propose a comprehensive multi-parametric analysis of several  
15 immunological parameters that define a MPM immune-signature, reliably applied to both  
16 pleural fluid and tissue routinely collected in standard clinical practice. We are aware that our  
17 discriminating cut-off values, although significant, have been obtained in a small patient  
18 cohort, and we emphasize that the identification of the optimal cutoff was beyond the scope of  
19 this analysis. The parameters are now being validated in a larger prospective study, including  
20 discovery and validation cohorts, in order to improve the specificity of the proposed thresholds  
21 and evaluate the possible clinical utility of the immune-parameters found. In such ongoing  
22 study, refined grouping strategies will be adopted, in order to define more accurately the  
23 quantitative values of the immune-phenotypic parameters significantly correlated with patient  
24 survival and other clinical parameters. Only if the validation study will confirm this pilot  
25 experience, the immune biomarkers identified in the present study may be considered as

1 additional parameters to be analyzed - beyond the parameters already adopted to perform MPM  
2 diagnosis - in challenging clinical cases.

3 **Of note, this study** is the first one aimed to systematically characterize the immune-infiltrate of  
4 pleural fluid and tumor derived from the same patient. Our results indicated that the analysis  
5 of the intratumor immune-infiltrate – better than that of pleural fluid – **identifies** potential  
6 prognostic factors. **Given the high inter-patients and intra-patients variability observed in**  
7 **MPM, the larger prospective validation study will also clarify if the qualitative and quantitative**  
8 **differences in the intra-tumor immune-infiltrate may be correlated with specific histological,**  
9 **cyto-genetic and mutational features.** This may contribute to a more **accurate patients’**  
10 **stratification, for a rationale and personalized immune-therapy** of MPM.

## 11 **Funding**

12 This work was supported by Italian Association for Cancer Research (IG21408 to CR); Italian  
13 Ministry of University and Research (Future in Research program RBFR12SOQ1 to CR; Basic  
14 Research Funding Program, FABR2017 to LR and CR); Italian Ministry of Health (GR-2011-  
15 02348356 to LR; Italian Mesothelioma Network-CCM2012 to GVS), **Azienda Ospedaliera “SS.**  
16 **Antonio e Biagio e Cesare Arrigo” to GVS for the research activity “MESOLINE”,** University of  
17 Torino (Intramural Grant 2015 to SN and CR; Intramural Grant 2016 to LR; Intramural Grant  
18 2017 to JK); Fondazione Cassa di Risparmio di Torino (2016-2443 to CR). ICS is a post-  
19 doctoral research fellow supported by the Fondazione Franco e Marilisa Caligara for  
20 Multidisciplinary Sciences, Torino, Italy. VM is a PhD fellow of Erasmus Mundus-ERAWEB  
21 Action 2 program. **FN is a student of the Biomedical Sciences and Oncology PhD program.**

22 The funding institutions had no role in the study design, data collection and analysis, or in  
23 writing the manuscript.

24

## 25 **Acknowledgments**

1 We are grateful to Mr. Costanzo Costamagna, Dept of Oncology, University of Torino for the  
2 technical assistance.

3

#### 4 **References**

- 5 1. Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the  
6 horizon with novel therapeutic strategies. *Cancer Treat Rev.* 2015;41:27-34.  
7 <https://doi.org/10.1016/j.ctrv.2014.10.007>.
- 8 2. Stahel RA, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz  
9 I, Peters S. Searching for targets for the systemic therapy of mesothelioma. *Ann Oncol.*  
10 2015;26:1649-60. <https://doi.org/10.1093/annonc/mdv101>.
- 11 3. Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni  
12 P, Schlom J, Guadagni F, Hassan R. Malignant Mesothelioma Effusions Are Infiltrated by  
13 CD3(+) T Cells Highly Expressing PD-L1 and the PD-L1(+) Tumor Cells within These  
14 Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. *J Thorac Oncol.*  
15 2016;11:1993-2005. <https://doi.org/10.1016/j.jtho.2016.07.033>.
- 16 4. Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao  
17 X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards  
18 WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpennig KW, Jänne PA, Sholl LM,  
19 Hammerman PS, Wong KK, Bueno R. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural  
20 Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. *Cancer*  
21 *Immunol Res.* 2016;4:1038-48. <https://doi.org/10.1158/2326-6066.CIR-16-0171>.
- 22 5. Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B,  
23 Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo  
24 C, Hassan R. Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in

- 1 Mesothelioma Patients. *Clin Cancer Res.* 2018;24:2859-72. [https://doi.org/10.1158/1078-](https://doi.org/10.1158/1078-0432.CCR-17-3757)  
2 0432.CCR-17-3757.
- 3 6. Marcq E, Pauwels P, van Meerbeeck JP, Smits EL. Targeting immune checkpoints: New  
4 opportunity for mesothelioma treatment? *Cancer Treat Rev.* 2015;41:914-24.  
5 <https://doi.org/10.1016/j.ctrv.2015.09.006>.
- 6 7. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN.  
7 Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune  
8 responses. *Eur Respir J.* 2006;27:1086-95. <https://doi.org/10.1183/09031936.06.00135305>.
- 9 8. Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, Riganti C. Zoledronic  
10 acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.  
11 *Oncotarget.* 2015;6:1128-42. <https://doi.org/10.18632/oncotarget.2731>
- 12 9. Cornelissen R, Lievense LA, Maat AP, Hendriks RW, Hoogsteden HC, Bogers AJ, Hegmans  
13 JP, Aerts JG. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid  
14 malignant pleural mesothelioma. *PLoS One.* 2014;9:e106742.  
15 <https://doi.org/10.1371/journal.pone.0106742>.
- 16 10. Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP. Immunotherapy prospects in the  
17 treatment of lung cancer and mesothelioma. *Transl Lung Cancer Res.* 2014;3:34-45.  
18 <https://doi.org/10.3978/j.issn.2218-6751.2013.11.04>.
- 19 11. Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG.  
20 Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T  
21 Cell Suppression. *J Thorac Oncol.* 2016;11:1755-64.  
22 <https://doi.org/10.1016/j.jtho.2016.06.021>.
- 23 12. Chéné AL, d'Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau JF, Cellierin L,  
24 Delneste Y, Grégoire M, Blanquart C. Pleural Effusions from Patients with Mesothelioma

- 1 Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages. *J Thorac*  
2 *Oncol.* 2016;11:1765-73. <https://doi.org/10.1016/j.jtho.2016.06.022>.
- 3 13. Jackaman C, Yeoh TL, Acuil ML, Gardner JK, Nelson DJ. Murine mesothelioma induces  
4 locally-proliferating IL-10(+)TNF- $\alpha$ (+)CD206(-)CX3CR1(+) M3 macrophages that can be  
5 selectively depleted by chemotherapy or immunotherapy. *Oncoimmunology.*  
6 2016;5:e1173299. <https://doi.org/10.1080/2162402X.2016.1173299>.
- 7 14. Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D,  
8 Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello  
9 S, Scagliotti GV, Di Nicolantonio F, Taulli R. Bromodomain inhibition exerts its therapeutic  
10 potential in malignant pleural mesothelioma by promoting immunogenic cell death and  
11 changing the tumor immune-environment. *Oncoimmunology.* 2017;7:e1398874.  
12 <https://doi.org/10.1080/2162402X.2017.1398874>.
- 13 15. Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function  
14 of myeloid-derived suppressor cells. *Oncoimmunology.* 2015;5:e1004983.  
15 <https://doi.org/10.1080/2162402X.2015.1004983>
- 16 16. Tan Z, Zhou J, Cheung AK, Yu Z, Cheung KW, Liang J, Wang H, Lee BK, Man K, Liu L,  
17 Yuen KY, Chen Z. Vaccine-elicited CD8<sup>+</sup> T cells cure mesothelioma by overcoming tumor-  
18 induced immunosuppressive environment. *Cancer Res.* 2014;74:6010-21.  
19 <https://doi.org/10.1158/0008-5472.CAN-14-0473>.
- 20 17. Yu Z, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NTL, Man K, Liu L, Chen Z.  
21 Antigen spreading-induced CD8<sup>+</sup>T cells confer protection against the lethal challenge of wild-  
22 type malignant mesothelioma by eliminating myeloid-derived suppressor cells. *Oncotarget.*  
23 2015;6:32426-38. <https://doi.org/10.18632/oncotarget.5856>.
- 24 18. Ujiiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug  
25 LM, Adusumilli PS. The tumoral and stromal immune microenvironment in malignant pleural

1 mesothelioma: A comprehensive analysis reveals prognostic immune markers.  
2 *Oncoimmunology*. 2015;4:e1009285. [https://doi.org/ 10.1080/2162402X.2015.1009285](https://doi.org/10.1080/2162402X.2015.1009285)

3 19. Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, Trauet J, Copin  
4 MC, Dessaint JP, Porte H, Labalette M. Defect in recruiting effector memory CD8+ T-cells in  
5 malignant pleural effusions compared to normal pleural fluid. *BMC Cancer*. 2013;13:e324.  
6 <https://doi.org/10.1186/1471-2407-13-324>.

7 20. Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli  
8 GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.  
9 Malignant pleural mesothelioma immune microenvironment and checkpoint expression:  
10 correlation with clinical-pathological features and intratumor heterogeneity over time. *Ann*  
11 *Oncol*. 2018;29:1258-65. <https://doi.org/10.1093/annonc/mdy086>.

12 21. Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica  
13 V, Buttiglieri C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV. Molecular and  
14 Histopathological Characterization of the Tumor Immune Microenvironment in Advanced  
15 Stage of Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2018;13:124-33.  
16 <https://doi.org/10.1016/j.jtho.2017.09.1968>.

17 22. Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A,  
18 Martinez-Marti A, Martinez P, Felip E. Analysis of expression of programmed cell death 1  
19 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). *PLoS One*. 2015;10:e0121071.  
20 <https://doi.org/10.1371/journal.pone.0121071>

21 23. Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L,  
22 Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S. Immune biomarkers PD-  
23 1/PD-L1 and TLR3 in malignant pleural mesotheliomas. *Hum Pathol*. 2016;52:9-18.  
24 <https://doi.org/10.1016/j.humpath.2016.01.010>.

- 1 24. Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, Hammerman PS, Gill RR,  
2 Richards WG, Barbie DA, Bass AJ, Bueno R, English JM, Bittinger M, Wong KK. Fine needle  
3 aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the  
4 mesothelioma microenvironment. *Sci Rep*. 2016;6:e31745. <https://doi.org/10.1038/srep31745>.
- 5 25. Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E,  
6 Hens N, Pauwels P, van Meerbeeck JP, Smits EL. Prognostic and predictive aspects of the  
7 tumor immune microenvironment and immune checkpoints in malignant pleural  
8 mesothelioma. *Oncoimmunology*. 2016;6:e1261241.  
9 <https://doi.org/10.1080/2162402X.2016.1261241>.
- 10 26. Marcq E, Waele J, Audenaerde JV, Lion E, Santermans E, Hens N, Pauwels P, van  
11 Meerbeeck JP, Smits ELJ. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as  
12 immunotherapy checkpoint targets in effusions of mesothelioma patients. *Oncotarget*.  
13 2017;8:89722-35. <https://doi.org/10.18632/oncotarget.21113>
- 14 27. Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell  
15 DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi  
16 M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed  
17 malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-  
18 blind, placebo-controlled phase 2b trial. *Lancet Oncol*. 2017;18:1261-73.  
19 [https://doi.org/10.1016/S1470-2045\(17\)30446-1](https://doi.org/10.1016/S1470-2045(17)30446-1).
- 20 28. Lievens LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG.  
21 Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant  
22 mesothelioma patients. *Lung Cancer*. 2017;107:36-40.  
23 <https://doi.org/10.1016/j.lungcan.2016.04.015>.

- 1 29. Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in Immune Cell  
2 Content in Malignant Pleural Mesothelioma. *Int J Mol Sci.* 2018;19(4). pii: E1041.  
3 <https://doi.org/10.3390/ijms19041041>.
- 4 30. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines  
5 Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for  
6 diagnosis, treatment and follow-up. *Ann Oncol.* 2015;26 Suppl 5:v31-9.  
7 <https://doi.org/10.1093/annonc/mdv199>
- 8 31. Riganti C, Gazzano E, Gulino GR, Volante M, Ghigo D, Kopecka J. Two repeated low  
9 doses of doxorubicin are more effective than a single high dose against tumors overexpressing  
10 P-glycoprotein. *Cancer Lett.* 2015;360:219-26. <https://doi.org/10.1016/j.canlet.2015.02.008>.
- 11 32. De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. iNOS  
12 activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon  
13 cancer cells. *Mol Cancer.* 2009;8:e108. <https://doi.org/10.1186/1476-4598-8-108>.
- 14 33. Campia I, Buondonno I, Castella B, Rolando B, Kopecka J, Gazzano E, Ghigo D, Riganti  
15 C. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug  
16 Resistant Human Cancer Cells. *PLoS One.* 2015;10:e0126159.  
17 <https://doi.org/10.1371/journal.pone.0126159>.
- 18 34. Cornelissen R, Lievense LA, Robertus JL, Hendriks RW, Hoogsteden HC, Hegmans JP,  
19 Aerts JG. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to  
20 predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. *Lung*  
21 *Cancer.* 2015;88:332-37. <https://doi.org/10.1016/j.lungcan.2015.03.013>.
- 22 35. Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U. The PD-L1/PD-1  
23 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural  
24 effusions in lung cancer patients. *Cancer Immunol Immunother.* 2017;66:765-76.  
25 <https://doi.org/10.1007/s00262-017-1979-x>.

1 36. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. *Trends*  
2 *Immunol.* 2008;29:272-79. <https://doi.org/10.1016/j.it.2008.02.011>.

3

#### 4 **Figure legends**

#### 5 **Figure 1. Lymphocyte subtypes present in pleural fluid and tissue of malignant pleural** 6 **mesothelioma**

7 Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural  
8 mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from  
9 digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5)  
10 were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same  
11 patients were analyzed in parallel. **A-C.** Percentage of total (CD3<sup>+</sup>), T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and  
12 T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Data are presented as means±SD. **Values of 25<sup>th</sup>**  
13 **percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 52.00, 61.00, 66.00; pleuritis PT: 15.00, 21.00,**  
14 **26.75; MPM PF: 52.00, 62.00, 71.00; MPM PT: 37.75, 47.00, 58.75; MTS PF: 51.00, 55.00,**  
15 **64.00; MTS PT: 36.50, 41.00, 51.50 (panel A); pleuritis PF: 39.25, 52.00, 60.50; pleuritis PT:**  
16 **51.00, 61.00, 67.00; MPM PF: 48.25, 61.00, 70.25; MPM PT: 51.00, 56.00, 71.00; MTS PF:**  
17 **45.10, 51.50, 60.50; MTS PT: 54.00, 61.00, 67.50 (panel B); pleuritis PF: 2.90, 3.75, 5.98;**  
18 **pleuritis PT: 30.00, 41.00, 49.00; MPM PF: 25.00, 29.00, 33.00; MPM PT: 12.00, 15.00, 19.00;**  
19 **MTS PF: 14.50, 20.00, 26.00; MTS PT: 10.50, 11.00, 15.50 (panel C). \*\*\*p<0.001:**  
20 **MPM/MTS vs pleuritis; not significant: MPM vs MTS. D.** Disaggregated data of T-cytotoxic  
21 cells percentage in PF and PT from the same patient. **Dotted line: 6.3% cut-off value in PF**  
22 **(false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). E.** Percentage of  
23 T-regulatory (Treg; CD4<sup>+</sup> CD25<sup>+</sup>CD127<sup>low</sup>) cells. Data are presented as means±SD. **Values of**  
24 **25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 0.90, 1.20, 1.50; pleuritis PT: 0.30, 0.50,**  
25 **0.90; MPM PF: 2.73, 2.95, 3.48; MPM PT: 2.10, 2.80, 3.25; MTS PF: 1.10, 1.25, 1.50; MTS**

1 PT: 0.75, 1.10, 1.25. \*\*\*p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS.  
2 F. Disaggregated data of Treg cells percentage in PF and PT from the same patient. Dotted  
3 line: 1.4% cut-off value in PF; dashed line: 1.1% cut-off value in PT (false negative: 0%; false  
4 positive: 11%; sensitivity: 100%; specificity: 89%)

5 **Figure 2. Macrophage and myeloid-derived suppressor cell subtypes present in pleural**  
6 **fluid and pleural tissue of malignant pleural mesothelioma**

7 Cells collected from pleural fluid (PF) of patients with pleuritis (n=63), malignant pleural  
8 mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from  
9 digested pleural tissue (PT) of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5)  
10 were analyzed by flow cytometry. In n=9 pleuritis and n=20 MPM, PF and PT from the same  
11 patients were analyzed in parallel. A. Percentage of macrophages (CD14<sup>+</sup>CD68<sup>+</sup> cells). Data  
12 are presented as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF:  
13 15.00, 19.00, 31.00; pleuritis PT: 21.00, 25.00, 32.00; MPM PF: 49.25, 61.00, 71.00; MPM  
14 PT: 41.75, 55.00, 62.25; MTS PF: 48.25, 54.00, 66.25; MTS PT: 48.50, 65.00, 69.50. \*p<0.01,  
15 \*\*\*p<0.001: MPM/MTS vs pleuritis. B. Disaggregated data of macrophage percentage in PF  
16 and PT from the same patient. Dotted line: 34% cut-off value in PF, dashed line: 35% cut-off  
17 value in PT (false negative: 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). C.  
18 Percentage of M2-macrophages (CD68<sup>+</sup>CD206<sup>+</sup>Arg1<sup>+</sup> cells). Data are presented as means±SD.  
19 Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 17.25, 22.00, 28.00; pleuritis  
20 PT: 23.00, 28.00, 34.50; MPM PF: 45.00, 55.00, 62.25; MPM PT: 56.00, 60.00, 68.25; MTS  
21 PF: 41.25, 44.00, 57.00; MTS PT: 53.00, 64.00, 65.00. \*\*\*p<0.001: MPM/MTS vs pleuritis.  
22 D. Disaggregated data of M2-macrophage percentage in PF and PT from the same patient.  
23 Dotted line: 29% cut-off value in PF, dashed line: 36% cut-off value in PT (false negative:  
24 0%; false positive: 0%; sensitivity: 100%; specificity: 100%). E. Percentage of granulocytic  
25 myeloid-derived suppressor cells (Gr-MDSC; CD11b<sup>+</sup>CD14<sup>-</sup>CD15<sup>+</sup> cells). Data are presented

1 as means±SD. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 2.20, 2.80, 3.68;  
2 pleuritis PT: 2.10, 2.60, 3.10; MPM PF: 11.23, 13.05, 17.73; MPM PT: 11.80, 13.15, 17.03;  
3 MTS PF: 3.28, 5.15, 6.30; MTS PT: 4.80, 5.10, 7.70. \*\*\*p<0.001: MPM vs pleuritis;  
4 °°°p<0.001: MPM vs MTS. **F.** Disaggregated data of Gr-MDSC percentage in PF and PT from  
5 the same patient. Dashed line: 5.1% cut-off value in PF and PT (false negative: 0%; false  
6 positive: 0%; sensitivity: 100%; specificity: 100%). **G.** Percentage of monocytic myeloid  
7 derived suppressor cells (Mo-MDSC; CD11b<sup>+</sup>CD14<sup>+</sup>CD15<sup>low</sup> cells). Data are presented as  
8 means±SD. \*\*\*p<0.001: MPM vs pleuritis; °°°p<0.001: MPM vs MTS. Values of 25<sup>th</sup>  
9 percentile, median, 75<sup>th</sup> percentile: pleuritis PF: 2.10, 2.40, 3.45; pleuritis PT: 2.13, 2.75, 3.18;  
10 MPM PF: 5.90, 8.20, 10.20; MPM PT: 8.10, 9.75, 11.28; MTS PF: 1.30, 2.30, 2.90; MTS PT:  
11 1.90, 2.35, 2.80. **H.** Disaggregated data of Mo-MDSC percentage in PF and PT from the same  
12 patient. Dotted line: 3.6% cut-off value in PF, dashed line: 4.2% cut-off value in PT (false  
13 negative: 0%; false positive: 11%; sensitivity: 100%; specificity: 89%).

14 **Figure 3. Intratumor myeloid-derived suppressor cells determines CD8<sup>+</sup> T-lymphocytes**  
15 **anergy**

16 1×10<sup>4</sup> sorted intra-tissue Gr-MDSC and Mo-MDSC derived from pleuritis (n=10), MPM  
17 (n=12) and other tumors metastatizing to pleura (MTS; n=4) were seeded and analyzed after  
18 24 h (panels **A-C**), or co-cultured (panels **D-F**) for 6 days with the sorted intra-tissue  
19 CD3<sup>+</sup>CD8<sup>+</sup>T-cytotoxic lymphocytes of the corresponding patient (autologous setting). When  
20 indicated, Gr-MDSC and Mo-MDSC from MPM patients were cultured with T-cytotoxic  
21 lymphocytes from pleuritis patients (pleu/MPM setting; n=8). **A-C.** Intracellular ROS (**panel**  
22 **A**) were measured fluorimetrically, nitrite (**panel B**) and kynurenine (**panel C**) released in the  
23 supernatants were measured spectrophotometrically. Data are presented as means±SD. Values  
24 of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis Gr-MDSC: 0.59 0.79, 0.94; pleuritis Mo-  
25 MDSC: 0.43, 0.65, 0.80; MPM Gr-MDSC: 2.08, 2.40, 2.78; MPM Mo-MDSC: 1.78, 2.20,

1 2.68; MTS Gr-MDSC: 0.61, 0.72, 0.81; MTS Mo-MDSC: 0.43, 0.66, 0.82 (panel A); pleuritis  
2 Gr-MDSC: 1.58, 2.00, 2.45; pleuritis Mo-MDSC: 1.60, 2.10, 2.95; MPM Gr-MDSC: 8.20,  
3 9.75, 12.25; MPM Mo-MDSC: 6.05, 6.85, 8.55; MTS Gr-MDSC: 1.30, 1.75, 2.65; MTS Mo-  
4 MDSC: 1.63, 2.15, 2.45 (panel B); pleuritis Gr-MDSC: 0.55, 0.72, 0.82; pleuritis Mo-MDSC:  
5 0.72, 0.87, 1.16; MPM Gr-MDSC: 3.73, 4.14, 4.85; MPM Mo-MDSC: 4.25, 5.26, 5.35; MTS  
6 Gr-MDSC: 0.59, 0.89, 1.19; MTS Mo-MDSC: 0.78, 1.00, 1.24 (panel C). \*p<0.01, \*\*p<0.005,  
7 \*\*\*p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM vs MTS. **D-F.** The  
8 proliferation of T-cytotoxic lymphocytes (panel D) was measured radiometrically, the  
9 percentage of CD8<sup>+</sup>CD107a<sup>+</sup>lymphocytes (panel E) was measured by flow cytometry, the  
10 amount of IFN- $\gamma$  (panel F) in the supernatants was measured by ELISA. The proliferation of  
11 T-lymphocytes in the absence of anti-CD3/anti-CD28 dynabeads, used as negative control, was  
12 <3500 cpm for all experimental conditions. Data are presented as means $\pm$ SD. Values of 25<sup>th</sup>  
13 percentile, median, 75<sup>th</sup> percentile: pleuritis Gr-MDSC: 18.09, 23.12, 26.03; pleuritis Mo-  
14 MDSC: 27.53, 30.4, 34.62; MPM Gr-MDSC: 2.42, 4.04, 5.00; MPM Mo-MDSC: 4.03, 5.71,  
15 6.84; MTS Gr-MDSC: 16.66, 22.69, 28.46; MTS Mo-MDSC: 23.27, 31.72, 33.96; pleu/MPM  
16 Gr-MDSC: 5.33, 5.80, 7.19; pleu/MPM Mo-MDSC: 6.44, 8.25, 11.70 (panel D); pleuritis Gr-  
17 MDSC: 2.08, 2.60, 2.83; pleuritis Mo-MDSC: 2.48, 3.00, 3.25; MPM Gr-MDSC: 0.40, 0.60,  
18 0.80; MPM Mo-MDSC: 0.45, 0.80, 1.05; MTS Gr-MDSC: 1.95, 2.65, 3.05; MTS Mo-MDSC:  
19 2.83, 3.05, 3.65; pleu/MPM Gr-MDSC: 0.53, 0.75, 0.80; pleu/MPM Mo-MDSC: 0.40, 0.65,  
20 0.88 (panel E); pleuritis Gr-MDSC: 409.50, 441, 636.50; pleuritis Mo-MDSC: 459.80, 497.50,  
21 521.00; MPM Gr-MDSC: 111.80, 151.00, 203.30; MPM Mo-MDSC: 147.00, 177.00, 236.00;  
22 MTS Gr-MDSC: 322.00, 463.50, 506.80; MTS Mo-MDSC: 373.80, 480.00, 585.50;  
23 pleu/MPM Gr-MDSC: 168.80, 204.50, 263.80; pleu/MPM Mo-MDSC: 209.80, 298.00, 335.80  
24 (panel F). \*\*p<0.005, \*\*\*p<0.001: MPM vs pleuritis; °p<0.01, °°p<0.005, °°°p<0.001: MPM

1 vs MTS in autologous settings; # $p<0.01$ , ### $p<0.001$ : pleu/MPM setting vs pleuritis autologous  
2 setting.

3 **Figure 4. Immune-checkpoint expression in T-lymphocytes contained in pleural fluid and**  
4 **pleural tissue**

5 Cells collected from pleural fluid of patients with pleuritis (n=63), malignant pleural  
6 mesothelioma (MPM; n=49) and other tumors metastatizing to pleura (MTS; n=32), and from  
7 digested pleural tissue of patients with pleuritis (n=16), MPM (n=33) and MTS (n=5) were  
8 analyzed by flow cytometry. Data are presented as means±SD. **A-B.** Percentage of PD-1<sup>+</sup>T-  
9 helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile,  
10 median, 75<sup>th</sup> percentile: pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 2.45, 4.60, 5.60; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 2.50, 3.90,  
11 5.50; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 15.53, 18.30, 22.65; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 14.83, 17.65, 21.38; MTS  
12 CD3<sup>+</sup>CD4<sup>+</sup>: 7.95, 10.20, 12.30; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 7.03, 9.00, 11.33 (panel A); pleuritis  
13 CD3<sup>+</sup>CD4<sup>+</sup>: 2.10, 3.15, 4.10; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 2.03, 2.90, 4.18; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 10.20,  
14 12.50, 16.15; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 11.28, 15.20, 18.05; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 3.60, 4.30, 6.50; MTS  
15 CD3<sup>+</sup>CD8<sup>+</sup>: 3.10, 6.20, 8.15 (panel B). \*\*\* $p<0.001$ : MPM vs pleuritis; ° $p<0.01$ , °° $p<0.001$ :  
16 MPM vs MTS. **C-D.** Percentage of LAG-3<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic  
17 (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis  
18 CD3<sup>+</sup>CD4<sup>+</sup>: 1.90, 2.80, 4.15; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 1.90, 2.80, 4.15; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 10.83,  
19 13.35, 16.25; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 8.83, 10.60, 14.05; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 3.88, 7.20, 8.40; MTS  
20 CD3<sup>+</sup>CD8<sup>+</sup>: 3.75, 7.15, 8.60 (panel C); pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1.50, 1.85, 2.10; pleuritis  
21 CD3<sup>+</sup>CD8<sup>+</sup>: 1.60, 1.80, 2.18; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 8.38, 10.50, 14.28; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 8.10,  
22 10.50, 14.10; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 3.40, 4.60, 5.40; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 2.95, 4.10, 4.65 (panel D).  
23 \*\*\* $p<0.001$ : MPM vs pleuritis; ° $p<0.01$ , °° $p<0.005$ , °°° $p<0.001$ : MPM vs MTS. **E-F.**  
24 Percentage of TIM-3<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes.  
25 Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1, 1.80, 2.48; pleuritis

1 CD3<sup>+</sup>CD8<sup>+</sup>: 0.90, 1.35, 1.70; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 6.10, 7.30, 8.40; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 6.65, 8.30,  
2 10.70; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 2.18, 3.85, 4.43; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 1.98, 3.15, 4.13 (panel E); pleuritis  
3 CD3<sup>+</sup>CD4<sup>+</sup>: 1.13, 1.50, 2.05; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 1.20, 1.35, 1.58; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 6.18,  
4 8.10, 8.53; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 6.78, 9.10, 10.20; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 1.25, 1.60, 2.20; MTS  
5 CD3<sup>+</sup>CD8<sup>+</sup>: 1.15, 1.40, 1.85 (panel F). \*\*\*p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001:  
6 MPM vs MTS. **G-H.** Percentage of CTLA-4<sup>+</sup>T-helper (CD3<sup>+</sup>CD4<sup>+</sup>) and T-cytotoxic  
7 (CD3<sup>+</sup>CD8<sup>+</sup>) lymphocytes. Values of 25<sup>th</sup> percentile, median, 75<sup>th</sup> percentile: pleuritis  
8 CD3<sup>+</sup>CD4<sup>+</sup>: 1.20, 1.40, 1.90; pleuritis CD3<sup>+</sup>CD8<sup>+</sup>: 0.90, 1.30, 1.58; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 1.10,  
9 1.60, 1.90; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 1.10, 1.20, 1.50; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 1.18, 1.50, 2.10; MTS  
10 CD3<sup>+</sup>CD8<sup>+</sup>: 1.20, 1.30, 1.80 (panel G); pleuritis CD3<sup>+</sup>CD4<sup>+</sup>: 1.10, 1.20, 2.05; pleuritis  
11 CD3<sup>+</sup>CD8<sup>+</sup>: 1.25, 1.40, 1.70; MPM CD3<sup>+</sup>CD4<sup>+</sup>: 1.30, 1.80, 2.10; MPM CD3<sup>+</sup>CD8<sup>+</sup>: 1.20, 1.50,  
12 1.90; MTS CD3<sup>+</sup>CD4<sup>+</sup>: 1.45, 1.70, 2.38; MTS CD3<sup>+</sup>CD8<sup>+</sup>: 1.13, 1.40, 1.73 (panel H).

13 **Figure 5. Immune-checkpoint ligands expressed in malignant pleural mesothelioma cells**  
14 Mesothelial cells collected from patients with pleuritis (n=24), malignant pleural mesothelioma  
15 cells (MPM; n=33) or cells from different tumors metastatizing to pleura (MTS; n=16), were  
16 analyzed by flow cytometry for the expression of PD-L1 (panel A), LAG-3 (panel B), TIM-3  
17 (panel C), GAL-9 (panel D). Data are presented as means±SD. Values of 25<sup>th</sup> percentile,  
18 median, 75<sup>th</sup> percentile: pleuritis: 2.55, 3.60, 4.35; MPM: 15.05, 17.25, 22.95; MTS: 5.60, 9.30,  
19 12.70 (panel A); pleuritis: 1.43, 1.95, 2.83; MPM: 7.40, 9.10, 11.25; MTS: 2.40, 4.10, 5.10  
20 (panel B); pleuritis: 1.20, 1.90, 2.73; MPM: 7.35, 8.70, 10.25; MTS: 1.65, 2.40, 5.35 (panel  
21 C); pleuritis: 1.30, 2.40, 6.23; MPM: 13.40, 17.20, 21.50; MTS: 4.70, 7.80, 9.25 (panel  
22 D).\*\*\*p<0.001: MPM vs pleuritis; °°p<0.005, °°°p<0.001: MPM vs MTS.

1 **Table 1. Survival analysis according to the immune-phenotypic parameter characterizing**  
 2 **mesothelioma patients**

Immune-population	Sample	PFS (months) (95% CI)	p value	OS (months) (95% CI)	p value
CD3 <sup>+</sup> CD8 <sup>+</sup> low vs CD3 <sup>+</sup> CD8 <sup>+</sup> high	PF	6.3±1.6 vs 6.3±1.0 (5.0-8.3)	0.913	10.0±2.2 vs 10.8±1.1 (8.2-12.7)	0.6927
Treg low vs Treg high	PF	6.0±1.1 vs 7.0±1.6 (4.7-8.1)	0.496	10.8±1.6 vs 9.7±1.4 (8.2-12.7)	0.4347
M2 low vs M2 high	PF	7.0±1.3 vs 5.7±1.0 (4.7-7.8)	0.2851	10.9±1.5 vs 9.8±1.9 (8.2-12.7)	0.7424
Gr-MDSC low vs Gr-MDSC high	PF	7.1±1.1 vs 5.6±1.3 (4.6-8.1)	0.3351	10.6±1.4 vs 10.8±2.2 (8.2-13.1)	0.4522
Mo-MDSC low vs Mo-MDSC high	PF	6.8±1.2 vs 5.9±1.4 (4.4-8.1)	0.8755	10.8±1.6 vs 9.4±1.7 (7.9-12.5)	0.5498
CD4 <sup>+</sup> PD-1 <sup>+</sup> low vs CD4 <sup>+</sup> PD-1 <sup>+</sup> high	PF	5.7±1.3 vs 7.3±1.1 (4.7-8.1)	0.713	8.6±1.5 vs 12.4±1.6 (8.2-12.7)	0.1126
CD4 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD4 <sup>+</sup> LAG-3 <sup>+</sup> high	PF	7.2±1.4 vs 7.3±1.1 (5.0-8.4)	0.4585	9.6±2.5 vs 10.9±1.1 (8.2-12.7)	0.7886
CD4 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD4 <sup>+</sup> TIM-3 <sup>+</sup> high	PF	8.1±1.1 vs 5.0±1.3 (4.9-8.4)	0.1047	11.9±1.2 vs 9.1±2.1 (8.4-12.9)	0.5417
CD8 <sup>+</sup> PD-1 <sup>+</sup> low vs CD8 <sup>+</sup> PD-1 <sup>+</sup> high	PF	7.2±1.3 vs 6.8±1.2 (5.3-8.8)	0.6309	9.4±2.0 vs 10.0±1.4 (7.6-11.9)	0.9571
CD8 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD8 <sup>+</sup> LAG-3 <sup>+</sup> high	PF	6.5±1.4 vs 4.8±0.8 (4.1-7.2)	0.2127	11.0±1.8 vs 10.1±1.9 (8.1-13.0)	0.8569
CD8 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD8 <sup>+</sup> TIM-3 <sup>+</sup> high	PF	7.7±1.1 vs 4.3±1.2 (4.31-7.6)	0.0956	11.0±1.6 vs 9.7±1.6 (8.2-12.3)	0.5441
CD3 <sup>+</sup> CD8 <sup>+</sup> low vs CD3 <sup>+</sup> CD8 <sup>+</sup> high	PT	7.4±1.0 vs 8.0±1.3 (6.1-9.2)	0.8624	9.6±1.4 vs 10.3±1.3 (8.3-11.9)	0.9594
Treg low vs Treg high	PT	9.1±1.8 vs 4.7±1.4 (6.1-9.3)	<b>0.0172</b>	12.1±1.2 vs 7.6±1.0 (8.3-11.9)	<b>0.0046</b>
M2 low vs M2 high	PT	7.6±1.7 vs 8.8±1.1 (6.4-10.2)	0.8228	10.4±1.4 vs 9.3±1.2 (8.1-11.7)	0.4016
Gr-MDSC low vs Gr-MDSC high	PT	9.1±1.1 vs 5.6±1.0 (5.9-9.2)	<b>0.0427</b>	11.3±1.3 vs 7.5±1.1 (7.6-11.2)	<b>0.037</b>
Mo-MDSC low vs Mo-MDSC high	PT	11.2±1.2 vs 7.3±1.4 (7.7-11.5)	<b>0.0178</b>	11.1±1.7 vs 8.0±1.0 (8.1-11.4)	<b>0.026</b>
CD4 <sup>+</sup> PD-1 <sup>+</sup> low vs CD4 <sup>+</sup> PD-1 <sup>+</sup> high	PT	7.9±1.0 vs 7.9±1.7 (6.2-9.5)	0.6616	11.4±1.1 vs 8.3±1.1 (8.5-11.8)	<b>0.043</b>
CD4 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD4 <sup>+</sup> LAG-3 <sup>+</sup> high	PT	8.3±1.1 vs 7.0±1.3 (6.1-9.3)	0.364	11.5±1.4 vs 8.0±0.9 (8.0-11.5)	<b>0.0077</b>
CD4 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD4 <sup>+</sup> TIM-3 <sup>+</sup> high	PT	6.8±1.6 vs 8.4±0.9 (6.1-9.4)	0.7595	11.7±1.2 vs 7.8±1.2 (8.0-11.7)	<b>0.044</b>
CD8 <sup>+</sup> PD-1 <sup>+</sup> low vs CD8 <sup>+</sup> PD-1 <sup>+</sup> high	PT	7.8±1.3 vs 7.9±1.2 (6.2-9.5)	0.9333	10.3±1.3 vs 10.0±1.2 (8.4-11.8)	0.9315
CD8 <sup>+</sup> LAG-3 <sup>+</sup> low vs CD8 <sup>+</sup> LAG-3 <sup>+</sup> high	PT	6.7±1.3 vs 8.0±1.1 (5.7-9.0)	0.6298	9.7±1.5 vs 10.6±1.1 (8.3-11.9)	0.9219
CD8 <sup>+</sup> TIM-3 <sup>+</sup> low vs CD8 <sup>+</sup> TIM-3 <sup>+</sup> high	PT	6.8±1.7 vs 8.4±0.8 (6.1-9.3)	0.7423	8.5±1.6 vs 10.6±1.2 (8.0-11.6)	0.574

3 The median values of CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes, Treg, M2-macrophages, Gr-MDSC, Mo-  
 4 MDSC, CD4<sup>+</sup>PD-1<sup>+</sup>, CD4<sup>+</sup>LAG-3<sup>+</sup>, CD4<sup>+</sup>TIM-3<sup>+</sup>, CD8<sup>+</sup>PD-1<sup>+</sup>, CD8<sup>+</sup>LAG-3<sup>+</sup>, CD8<sup>+</sup>TIM-3<sup>+</sup>  
 5 cells was calculated in pleural fluid (PF; n=49) and pleural tissue (PT; n=33). Patients were  
 6 classified as “low” or “high” if the percentage of each population was low or equal/higher than  
 7 the median value. Progression free survival (PFS) and overall survival (OS) probability were  
 8 calculated using the Kaplan-Meier method, and expressed as mean±SD (months). CI:  
 9 confidence interval. Significant values are indicated by bold characters.

- 1 **Supplemental materials**
- 2 **Supplemental data 1. Supplemental Figure 1.tif**
- 3 **Supplemental data 2. Supplemental Table 1.docx**
- 4 **Supplemental data 3. Supplemental Table 2.docx**
- 5 **Supplemental data 4. Supplemental Figure 2.tif**
- 6 **Supplemental data 5. Supplemental Figure 3.tif**
- 7 **Supplemental data 6. Supplemental Figure 4.tif**
- 8 **Supplemental data 7. Supplemental Figure 5.tif**
- 9 **Supplemental data 8. Supplemental Figure 6.tif**
- 10 **Supplemental data 9. Supplemental Figure 7.tif**
- 11 **Supplemental data 10. Supplemental Figure 8.tif**